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Half-Baked: The Science and Politics of 
Legal Pot 
Joëlle Anne Moreno* 
ABSTRACT 
 
Weed, herb, grass, bud, ganja, Mary Jane, hash oil, sinsemilla, 
budder, and shatter. Marijuana – whether viewed as a medicine or 
intoxicant – is fast becoming a part of everyday life, with the CDC 
reporting 7,000 new users every day and the American market projected 
to grow to $20 billion by 2020.  Based on early campaign rhetoric, by that 
same year the U.S. could have a pro-marijuana president. 
 Despite its growing acceptance and popularity, marijuana remains 
illegal under federal law. Like heroin, LSD, and ecstasy, marijuana is a 
DEA Schedule I drug reflecting a Congressional determination that 
marijuana is both overly addictive and medically useless. 
 So what is the truth about pot?  The current massive pro-marijuana 
momentum and increased use, obscures the fact that we still know almost 
nothing about marijuana’s treatment and palliative potential.  Marijuana’s 
main psychoactive chemical is THC; but it also contains over 500 other 
chemicals with unknown physiological and psychological effects that vary 
based on dosage and consumption method. Medical marijuana may be 
legal in 32 states and supported by 84% of Americans, but federal 
constraints shield marijuana from basic scientific inquiry.  This means that 
lawmakers and voters are enthusiastically supporting greater access to a 
drug without demanding critical scientific data.  For policymaking 
purposes, this data should include marijuana’s short and long-term brain 
 
*Joëlle Anne Moreno, Professor of Law & Associate Dean for Faculty, Florida 
International University College of Law, Miami, FL. My son Adam suggested I simply 
dedicate this Article “to funions.”  That would have been hilarious, but misleading. Kurt 
Vonnegut was probably right that “alcohol and marijuana used in moderation, plus loud 
usually low-class music, makes stress and boredom infinitely more bearable;” but I 
personally rely on Cabernet and not cannabis. Many law professors use this space to 
advertise their (one can only suspect imaginary) personal mentorship by a bevvy of famous 
jurists and academics, which would have been fun to include given the topic. Instead I just 
want to thank my team – Adam, his brother Nathan, and their father Ken. Work can be 
interesting and useful - but you are my life. 
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effects, possible lung and cardiac implications, chemical interactions with 
alcohol and other drugs, addiction risks, pregnancy and breast-feeding 
concerns, and the effects of secondhand smoke. 
 This Article treats marijuana as a significant contemporary science 
and law problem.  It focuses on the fundamental question of regulating a 
substance that has not been adequately researched. The Article examines 
the extant scientific data, deficiencies, and inconsistencies and explains 
why legislators should not rely on copycat laws governing alcohol or 
prescription narcotics. It also explores how marijuana’s hybrid federal 
(illegality)/state (legality) raises compelling theoretical and practical 
Constitutional questions of preemption, the anti-commandeering rule, and 
congressional spending power. Marijuana legalization has, thus far, been 
treated as a niche academic concern.  This approach is short-sighted and 
narrowminded.  Marijuana regulation implicates the reach of national drug 
policy, the depth of state sovereignty, and the shared obligation to ensure 
the health and safety of our citizenry. 
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I. INTRODUCTION 
In the movie This is the End (2013), a group of stoner actors gather 
at James Franco’s house unaware of the impending Apocalypse which, 
like all cinematic disasters, will force each of them to reconsider their life 
choices and priorities. 
Jay Baruchel:Can we please go to f***ing Carl’s Jr.? 
Seth Rogen: Uh, I would love to, but I’m on a. . . I can’t really eat that 
stuff right now. I’m on a. . . I’m on this cleanse . . . . 
Jay Baruchel: So you’re not drinking, you’re not smoking weed? 
Seth Rogen: Oh, no. I’m drinking, I’m smoking weed. I’m on a 
cleanse, I’m not psychotic.1  
In an art imitates life cinematic moment, Seth Rogen speaks for 
America. Marijuana is fast becoming an essential element of everyday life. 
 
 1. THIS IS THE END (Columbia Pictures Corp. 2013); see also This Is the End – 
Quotes, IMDB, https://imdb.to/2RjwQL3 (last visited Mar. 18, 2019). 
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As the New York Times similarly and rather humorously reported on 
June 21, 2018, “decriminalizing marijuana has left pot smoke the signature 
olfactory experience of New York . . . .”2 The shift from the urban 
summertime stink of rotting garbage to the urbane odor of cultivated pot 
is only partly welcome. Wonder Woman, a currently trendy cannabis 
strain, has been described as a powerful “mostly skunky smell with notes 
of fruit and jet fuel.”3 But in New York City and elsewhere, marijuana is 
now an everyday experience, even for those who follow the late First Lady 
Nancy Reagan’s signature advice— “just say no.”4 
A. Introduction to Legal Pot 
Marijuana legalization advocacy is at an all-time high.5 The current 
public debate began in the late 1990s. Over the past three decades, pro-
legalization forces have persuasively argued that the advantages of 
medical marijuana (e.g., potential therapeutic applications, avoiding the 
prosecution of otherwise law-abiding medical users, and preventing the 
disparate prosecution of minorities for low level crimes) outweigh the 
disadvantages (e.g., addiction possibility, increased roads and highway 
safety concerns, accidental ingestion, and potential short or long-term 
psychological and/or physiological risks). 
Despite widespread state legalization, marijuana’s medical potential 
remains uncharted, while the enforcement of marijuana laws where pot 
remains illegal is a massive, problematic, and costly undertaking. This is 
especially concerning because “[o]f the 8.2 million marijuana arrests 
 
 2. Ginia Bellafante, Marijuana: The Signature Olfactory Experience of New York, 
N.Y. TIMES (June 21, 2018), https://nyti.ms/2zr0ua0. 
 3. Id. 
 4. See Michael McGrath, Nancy Reagan and the negative impact of the ‘Just Say No’ 
anti-drug campaign, THE GUARDIAN (Mar. 8, 2016, 2:23 PM), https://bit.ly/2qu6Dvy 
(arguing that the mid-80s “Just Say No” campaign was ineffective because it “aligned 
‘drugs’ (non-specific in terms of type and method of ingestion) with a dangerous and 
roughly defined ‘other’, and presented them as the consequence of collective personal 
failure in affected communities rather than a public health crisis for millions of 
Americans”); see also Scott O. Lilienfeld & Hal Arkowitz, Why “Just Say No” Doesn’t 
Work, SCI. AM. MIND (Jan. 1, 2014), https://bit.ly/2gt9kNB (citing to the extensive data 
“reveal[ing]that teens enrolled in the [D.A.R.E.] program [Drug Abuse Resistance 
Education—a cornerstone of the “Just Say No” Prevention Program] were just as likely to 
use drugs as were those who received no intervention,” while additional data demonstrates 
that some D.A.R.E. programs paradoxically “backfire when it comes to the use of milder 
substances, such as alcohol and cigarettes . . . [and there is even] a slight tendency for teens 
who went through D.A.R.E. to be more likely to drink and smoke than adolescents not 
exposed to the program” because “D.A.R.E. may inadvertently convey the impression that 
alcohol and tobacco are innocuous by comparison”). 
 5. See Marijuana Legalization and Regulation, DRUG POL’Y ALLIANCE, 
https://bit.ly/2xfjncZ (last visited Mar. 18, 2019). 
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between 2001 and 2010, 88% were for simply having marijuana.6  The 
American Civil Liberties Union (ACLU) reports cannabis law 
enforcement costs state governments a total of $3.6 billion annually.7 
Given the high cost of arresting for low-level criminality, legal marijuana 
creates an irresistible win-win. Legalization offers state and local 
government a path to reduce law enforcement costs while simultaneously 
increasing revenue by creating new licensing, regulatory, and taxation 
income streams. 
Today, there may be a dispensary down the block from where you 
live—but make no mistake, pot is illegal. Since 1970, Congress has 
banned marijuana as a Schedule I drug under the Controlled Substances 
Act (CSA).8 Schedule I drugs are illegal by definition even in the absence 
of valid scientific substantiation. Marijuana’s Schedule I status is based 
solely on a five-decade-old congressional finding that pot, like heroin, 
LSD, and methylenedioxymethamphetamine (a.k.a. MDMA or ecstasy), 
has a high potential for abuse and has no currently accepted medical use 
in treatment.9  With marijuana now legal in most states, very little attention 
has been paid to its Schedule I status and its implications for scientific 
research. 
Despite its enduring federal illegality, today pot can be legally grown, 
used, bought, and sold in a growing number of states across the country. 
It is possible, but far from certain, that the current massive shift to greater 
 
 6. Marijuana Arrests by the Numbers, AM. CIVIL LIBERTIES UNION 
https://www.aclu.org/gallery/marijuana-arrests-numbers (last visited Mar. 18, 2019). 
 7. HUMAN RIGHTS WATCH & AM. CIVIL LIBERTIES UNION, EVERY 25 SECONDS: THE 
HUMAN TOLL OF CRIMINALIZING DRUG USE IN THE UNITED STATES 5, 185-86 (2016) 
(highlighting how U.S. drug policies affect human lives, including those charged with 
criminal drug offenses relating to the possession and use of marijuana). 
 8. Controlled Substances Act, 21 U.S.C. §§ 801–971 (2012 & Supp. 2017). The CSA 
provides that, “[e]xcept as authorized by this subchapter, it shall be unlawful for any person 
knowingly or intentionally– to manufacture, distribute, or dispense, or possess with intent 
to manufacture, distribute, or dispense, a controlled substance.” 21 U.S.C. § 841(a)(1). The 
CSA classifies controlled substances into five schedules and marijuana is classified as a 
Schedule I drug, which is the most restrictive category reserved for substances deemed to 
have high abuse potential and no currently accepted medical purpose, except for 
government-approved research projects. See 21 U.S.C. § 812(a)–(c); see also 21 U.S.C. § 
823(f). Under the CSA, the Attorney General and Secretary of Health and Human Services 
can add or remove “any drug or other substance” from the schedules. See 21 U.S.C. § 
811(a)–(b).  
 9. 21 C.F.R. § 1308.11(b)–(d) (2018) (providing a list of current Schedule I drugs, 
such as heroin, lysergic acid diethylamide (LSD), mescaline, and other hallucinogenic 
amphetamine derivatives); see also 21 U.S.C. § 812(b)(1) (2018) (emphasizing that 
Schedule I drugs have a “high potential for abuse . . . no currently accepted medical use in 
treatment in the United States . . . [and] a lack of accepted safety for use . . . under medical 
supervision”); 21 U.S.C. § 801(2) (declaring the congressional finding—as of the modern 
CSA’s enactment in 1970—that controlled substances like marijuana “have a substantial 
and detrimental effect on the health and general welfare of the American people.”). 
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legal marijuana use could eventually provide an increased evidence base 
of its effects provoking the federal government to remove current research 
obstacles. In the interim, the simultaneous legality and illegality of 
cannabis is unusual and intriguing. Local decriminalization clearly reflects 
intrastate interests, but as marijuana momentum increases, political, legal, 
and regulatory complexities transcend state line. At the same time, shifts 
in federal policy and enforcement protocols (most recently and notably 
between the Obama and Trump administrations) exacerbate preexisting 
federal-state tensions.10 As the recent heated debate about medical 
marijuana access for veterans demonstrates,11 the current delicate balance 
between federal and state law and policy cannot endure. A well-publicized 
February 2018 lawsuit seeking to resolve this problem through federal 
legalization of marijuana was dismissed;12 but future legal tensions and 
challenges are inevitable. 
In the U.S., legal pot was initially only available for medical 
purposes. In November 1996, California became the first state to legalize 
medicinal pot when voters passed Proposition 215.13 Proposition 215 
became California’s Compassionate Use Act, permitting patients (and 
their primary caregivers) to possess and cultivate marijuana—with a 
physician’s recommendation—for the treatment of various enumerated 
disorders.14 The California law also protects physicians from legal 
sanction if they recommend cannabis to their patients.15 State medical 
marijuana statutes enacted after California’s typically adopt a similar 
structure by insulating qualified patients and their doctors from arrest, 
prosecution, and civil sanction (e.g., fines or forfeiture).16 Many state laws 
also specifically permit designated caregivers to lawfully “possess, handle, 
 
 10. See infra notes 346–55 and accompanying text.  
 11. See Julio Ochoa, Veterans Lobby Federal Government for Medical Marijuana 
Access, WBUR (Sept. 19, 2018), https://wbur.fm/2PL8byq (highlighting that veterans 
around the country are calling on the federal government to reclassify marijuana to reflect 
its medical value because they say that they use the drug to treat conditions from pain to 
post-traumatic stress disorder).  
 12.  Washington v. Sessions, No. 17 Civ. 5625 (AKH), 2018 WL 1114758, at *3–10 
(S.D.N.Y. Feb. 26, 2018); see also Brendan Pierson, U.S. federal judge rejects challenge 
to marijuana prohibition, REUTERS. (Feb. 26, 2018, 7:35 PM), https://reut.rs/2ACDFlx 
(explaining that the U.S. District Court “ruled that the lawsuit must be dismissed because 
the plaintiffs had failed to use administrative procedures within the Drug Enforcement 
Administration (DEA) to challenge the ban,” but the decision “should not be understood 
as a factual finding that marijuana lacks any medical use in the United States”). 
 13. Compassionate Use Act of 1996, CAL. HEALTH & SAFETY CODE § 11362.5 (West 
2018) (originally enacted by California Proposition 215). 
 14. Id. 
 15. Id. § 11362.5(c). 
 16. Robert A. Mikos, On the Limits of Supremacy: Medical Marijuana and the States’ 
Overlooked Power to Legalize Federal Crime, 62 VAND. L. REV. 1421, 1430 (2009) 
(discussing N.M. STAT. ANN. § 26-2B-4(A) (West 2018)). 
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and even cultivate marijuana on behalf of qualified patients without fear 
of state-imposed sanctions.”17 The first wave of medicinal cannabis 
legalization (1996-2004) included Alaska, California, Colorado, Hawaii, 
Maine, Montana, Nevada, Oregon, Vermont, and Washington.18 
In 2001, the Supreme Court entered the medicinal cannabis debate. 
As discussed in more detail below, in United States v. Oakland Cannabis 
Buyers’ Cooperative,19 the Court rejected an argument that the California 
law had effectively created a new medicinal necessity exception to the 
CSA.20 Four years later, in Gonzales v. Raich,21 the Court would 
specifically uphold federal CSA marijuana enforcement as a proper 
exercise of Congressional Commerce Clause power.22 But Supreme Court 
intervention has done nothing to ameliorate federalism tensions or slow 
the tide of legalization. In the immediate wake of Raich, 32 additional 
states legalized medical marijuana, bringing the current total to 32 states 
plus the District of Columbia, Guam, and Puerto Rico.23 In 2014, poised 
to reenter the marijuana legalization debate, the Court sidestepped a case 
involving recreational use legalization.24 Nebraska and Oklahoma had 
sought to enjoin Colorado from implementing its recreational use statute, 
arguing that the new law “created a dangerous gap in the federal drug 
control system,” and that interstate commerce was implicated because 
“[m]arijuana flows from this gap into neighboring states.”25 The Court 
declined to even hear the case, although Justice Thomas and Justice Alito 
dissented from this decision.26 
Legal pot is increasingly popular among voters. By 2018, legalization 
for medical use was supported by 84% of Americans.27 That same year, 
the FDA enhanced medical pot’s mainstream appeal by approving the first 
 
 17.  Id. at 1431. 
 18. Id. at 1423 n.6; see also DRUG POL’Y ALLIANCE, supra note 5. 
 19. United States v. Oakland Cannabis Buyers’ Coop., 532 U.S. 483 (2001). 
 20. Id. at 494–96. 
 21.  Gonzales v. Raich, 545 U.S. 1 (2005). 
 22. Id. at 19–22. 
 23. See German Lopez, Marijuana is Legal for Medical Purposes in 32 States, VOX, 
http://bit.ly/2RCaLYi (last updated Nov. 14, 2018) (showing the 32 states that have 
legalized medical marijuana: Alaska, Arizona, Arkansas, California, Colorado, 
Connecticut, Delaware, Florida, Hawaii, Illinois, Maine, Maryland, Massachusetts, 
Michigan, Minnesota, Missouri, Montana, New Hampshire, Nevada, New Jersey, New 
Mexico, New York, North Dakota, Ohio, Oregon, Oklahoma, Pennsylvania, Rhode Island, 
Utah, Vermont, Washington, and West Virginia). 
 24. See generally Nebraska v. Colorado, 136 S. Ct. 1034 (2016) (No. 144, Orig.).  
 25. Petition for Writ of Certiorari at 3, Nebraska v. Colorado, 135 S. Ct. 2070 (Dec. 
18, 2014) (No. 144, Orig.). 
 26. See Nebraska, 136 S. Ct. at 1034 (Thomas, J., dissenting). 
 27. Kevin Loria, 23 health benefits of marijuana, BUSINESS INSIDER (Mar. 7, 2018, 
10:57 AM), https://read.bi/2wjbViN. 
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cannabis-derived medication.28 Legalization momentum increasingly 
includes support for recreational-use legalization or decriminalization. 
Over the past six years, each of the first nine states to legalize medicinal 
marijuana (except Hawaii) has legalized the possession of small amounts 
of recreational-use cannabis. Massachusetts and the District of Columbia 
have also similarly decriminalized limited recreational use. 
Public support for both medical and recreational cannabis has also 
started to cross party lines. The overall political popularity of cannabis 
legalization is now “at the highest point in nearly five decades.”29 Over the 
past decade, legal pot support has doubled. A 2017 Gallup poll revealed 
that 51% of Republicans now support marijuana legalization.30 This 
represents a dramatic increase from the 42% of Republicans who 
expressed support in 2016.31 Although increasingly bipartisan, voter 
support for legal pot remains stronger among Democrats (72%) and 
independents (67%).32 In these fractious times, it is tempting to view 
bipartisan support for marijuana legalization as a common shift in social 
values or personal liberty. But these assumptions naïvely underestimate 
the importance of marijuana money. 
B. Introduction to Marijuana Markets 
The national market for legal marijuana is exceptionally strong and 
expanding. Indeed, “the total estimated value of legal cannabis sales in the 
United States was $5.7 billion in 2015 and $7.1 billion in 2016.”33 As trips 
to the local dispensary replace trips to the local bar, states that have 
legalized both medical and recreational marijuana are capitalizing on new 
business, license, taxation, and other revenue opportunities.34 For 
example, Colorado reported 2015 cannabis sales and tax revenue of 
$88,239,323.35 Similarly, during the 2016 fiscal year, Washington state 
reported “local sales taxes and state business and occupation taxes on 
recreational and medical cannabis” totaling $53,410,661.36 
 
 28. Ryan Grenoble, First Cannabis-Derived Drug Approved by FDA for Medical Use, 
HUFFINGTON POST (last updated June 29, 2018), https://bit.ly/2Iw37tZ. 
 29. Justin McCarthy, Record-High Support for Legalizing Marijuana Use in U.S., 
GALLUP (Oct. 25, 2017), https://bit.ly/2QdoXXB. 
 30. Id. 
 31. Id. 
 32. Id. 
 33. NAT’L ACADS. OF SCIS., ENG’G, & MED., THE HEALTH EFFECTS OF CANNABIS AND 
CANNABINOIDS 377–378 (2017) [hereinafter THE HEALTH EFFECTS OF CANNABIS].   
 34. See Jeremy Berke & Skye Gould, Michigan became the 10th state to legalize 
recreational marijuana. This map shows every US state where the drug is legal, BUSINESS 
INSIDER (Nov. 7, 2018, 10:35 AM), https://read.bi/2E6hSmt. 
 35. THE HEALTH EFFECTS OF CANNABIS, supra note 33, at 378. 
 36. Id. 
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The future of new marijuana markets is even brighter. A recent report 
issued by BDS Analytics, a cannabis “business intelligence” research firm, 
estimates that California (with its population of 40 million people) should 
expect annual sales to hit $3.7 billion in 2018 and increase to $5.1 billion 
by 2019.37 Other cannabis industry analysts have been (unsurprisingly) 
equally bullish, estimating annual national marijuana sales revenue for 
2017—before California legalized recreational pot—as high as $10 
billion.38 On July 19, 2018, the business of marijuana first went 
mainstream when Tilray (a Canadian medical marijuana company) 
became the first marijuana company to go public on a major U.S. exchange 
(Nasdaq).39 In December 2018, Altria (the parent company of Philip 
Morris) announced a $2.4 billion investment in Cronos Group (a medical 
and recreational marijuana company based in Canada).40 
Marijuana market increases reflects a rapidly growing consumer 
base. Marijuana is now the most-used illicit drug and national 
consumption rates for all cannabis products are rising rapidly. In 2017, 
more than 11 million adults in the U.S. ages 18-25 smoked, vaped, or ate 
marijuana.41 Over the past decade, annual U.S. cannabis use has increased 
from 10.88% among Americans age twelve and older (2008–2009) to 
13.71% (2015–2016).42 In contrast, over the same seven-year period, 
annual cocaine use decreased from 2.01% to 1.84%, tobacco use declined 
from 28.06% to 23.72%, and alcohol use remained virtually constant, 
shifting just slightly from 51.74% to 51.21%.43 In 2016, the Centers for 
Disease Control and Prevention (“CDC”) reported that 2.5 million 
Americans annually start using marijuana, a daily average of 
 
 37. Jeremy Berke, California’s cannabis market is expected to soar to $5.1 billion — 
and it’s going to be bigger than beer, BUSINESS INSIDER (Feb. 28, 2018, 11:30 AM), 
https://read.bi/2DPBnio. 
 38. Jeremy Berke, The legal marijuana market is exploding — it’ll hit almost $10 
billion sales in this year, BUSINESS INSIDER (Dec. 8, 2017, 3:46 PM), 
https://read.bi/2F35BDy. 
 39. Chloe Aiello & Kellie Ell, Tilray joins Nasdaq in first US cannabis IPO, CNBC 
(July 23, 2018, 2:28 PM), https://cnb.cx/2JEeh0i; see also Gene Johnson, Canadian 
marijuana company has first US marijuana IPO, MERCURY NEWS (July 20, 2018, 12:01 
PM), https://bayareane.ws/2LHlyy2 (“Tilray isn’t the first pot company to trade on a major 
American stock exchange, but it is the first to do so with an IPO, a step that could boost 
credibility and confidence in the industry . . . .”). 
 40. Marlboro maker Altria buys big stake in Canadian marijuana company, CBS 
NEWS (Dec. 7, 2018, 9:55 AM), https://www.cbsnews.com/news/altria-marlboro-maker-
buys-big-stake-in-cronos-canadian-marijuana-company/. 
 41. DrugFacts: What is marijuana?, NAT’L INST. ON DRUG ABUSE, 
https://bit.ly/1QbDwb4 (last updated June 2018). 
 42. National Survey on Drug Use and Health: Comparison of 2008–2009 and 2015–
2016 Population Percentages, SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN., 
https://bit.ly/2jT6nGl (last visited Mar. 18, 2019) [hereinafter National Survey on Drug 
Use]. 
 43. Id. 
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approximately 7,000 new marijuana users.44 The National Institute for 
Drug Abuse (“NIDA”)45 is the research branch of the National Institutes 
of Health (“NIH”).46 NIDA, which is dedicated to “advanc[ing] science on 
the causes and consequences of drug use and addiction and to apply[ing] 
that knowledge to improve individual and public health,”47 estimates that 
22.2 million Americans use marijuana each month.48 Despite its rapid 
growth, some facts about marijuana use remain constant. For example, 
men are much more likely to use marijuana than women—and this gender 
gap has recently expanded.49 
Growing marijuana support, markets, and consumption are a global 
phenomenon. According to the World Health Organization (“WHO”), the 
annual rate of marijuana consumption worldwide is approximately 147 
million individuals or nearly 2.5% of the global population.50 For example, 
as of April 2017, Iceland reported the highest rate of cannabis use (18.3% 
of the population), with Nigeria (14.2%of the population), Canada (12.7% 
of the population), New Zealand (11% of the population), and Spain (9.2% 
of the population) also reporting significant consumption rates.51 Medical 
marijuana is currently legal in Canada, Australia, the Netherlands, France, 
Uruguay, Romania, Chile, the Czech Republic, Columbia, and Jamaica.52 
Marijuana is the third most commonly used recreational drug worldwide, 
following alcohol and tobacco.53 
 
 44. Alejandro Azofeifa et al., National Estimates of Marijuana Use and Related 
Indicators—National Survey on Drug Use and Health, United States, 2002–2014, 
MORBIDITY & MORTALITY WKLY. REP. SURVEILLANCE SUMMARIES, Sept. 2, 2016, at 1, 1, 
http://bit.ly/2GeopQN. 
 45. See NAT’L INST. ON DRUG ABUSE, https://bit.ly/1MNlOtZ (last visited Mar. 18, 
2019). 
 46. See NIH Organization, NAT’L INSTS. OF HEALTH, https://bit.ly/2iaGL8O (last 
visited Dec. 11, 2018). 
 47. National Institute on Drug Abuse (NIDA), NAT’L INSTS. OF HEALTH, 
https://bit.ly/2Ifv75M (last updated Nov. 28, 2018). 
 48. NAT’L INST. ON DRUG ABUSE, MARIJUANA RESEARCH REPORT 7, 
http://bit.ly/2Pyw8Zj (last updated June 2018) [hereinafter NIDA, MARIJUANA]. 
 49. Id. 
 50. Mary Barna Bridgeman et al., Medicinal Cannabis: History, Pharmacology, And 
Implications for the Acute Care Setting, 42 PHARMACY & THERAPEUTICS 180, 180 (2017). 
 51. Gavin Haines, Mapped: The Countries that Smoke the Most Cannabis, THE 
TELEGRAPH (Apr. 20, 2017, 1:00 PM), http://bit.ly/2zTsnJ7. 
 52. Sean Williams, 10 Countries (Aside from the U.S.) Where Some Form of Medical 
Marijuana is Legal, MOTLEY FOOL (May 15, 2016), http://bit.ly/2RToWsC. 
 53. LESLIE L. IVERSEN, THE SCIENCE OF MARIJUANA 188 (2d ed. 2008). 
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C. Introduction to Cannabis Science 
Despite widespread and growing use, we do not know if marijuana is 
efficacious or safe.54 In the 1970s, when the federal government deemed 
marijuana to be as addictive and medically useless as heroin, LSD, and 
methylenedioxymethamphetamine (ecstasy) by making it a Schedule I 
drug, the DEA effectively blocked scientific research.55 State legalization 
efforts typically ignore the paucity of the scientific evidence and do not 
seek Schedule I removal. This makes sense because neither legislators nor 
pro-marijuana voters would benefit from new information about health 
risks and the lack of evidence of health benefits has not diminished 
marijuana’s growing appeal. Over the past half-century, as cannabis use 
has grown and botanical geneticists continue to tinker with its chemical 
components, scientists’ efforts to understand how currently available 
marijuana products affect the human brain and body have been stymied. 
As a result, we find ourselves with a drug in everyday use but an 
inadequate body of scientific evidence to understand its myriad potential 
risks including: short and long-term brain effects (including potential 
effects on the developing brain); lung-health and/or cardiac implications; 
chemical interactions with alcohol and other legal and illegal drugs; 
fertility, safe pregnancy and/or breastfeeding concerns; and exposure to 
secondhand marijuana smoke.56 
 
 54. There are “potentially severe cognitive, psychotomimetic, and substance abuse-
related adverse effects associated with Δ9-tetrahydrocannabinol (THC) exposure that must 
be taken seriously, especially in young or cannabis-naïve patients.” Perry G. Fine & Mark 
J. Rosenfeld, The Endocannabinoid System, Cannabinoids, and Pain, RAMBAM 
MAIMONIDES MED. J., Oct. 2013, at 1, 4, http://bit.ly/2PySmun (noting that “fatalities have 
not been reported directly related to the toxicity of any cannabinoid, even with extremely 
high dosing”); see also Loria, supra note 27 (“More research would also shed light on the 
risks of marijuana. Even if there are legitimate uses for medicinal marijuana, that doesn’t 
mean all use is harmless.”). 
 55. Loria, supra note 27 (“[S]cientists say that limitations on marijuana research mean 
we still have big questions about its medicinal properties. In addition to CBD and THC, 
there are another 400 or so chemical compounds, more than 60 of which are cannabinoids. 
Many of these could have medical uses. But without more research, we won’t know how 
to best make use of those compounds.”); Cannabis and Cannabinoids (PDQ)–Health 
Professional Version: General Information, NAT’L CANCER INST., http://bit.ly/2RQL86L 
(last updated Aug. 16, 2018) (noting that any scientist seeking to engage in clinical 
cannabis research in the United States must “file an Investigational New Drug (IND) 
application with the FDA, obtain a Schedule I license from the U.S. Drug Enforcement 
Administration, and obtain approval from the National Institute on Drug Abuse”). 
 56. Charles W. Webb & Sandra M. Webb, Therapeutic Benefits of Cannabis: A 
Patient Survey, 73 HAW. J. MED. PUB. HEALTH 109, 109 (2014) (noting that “[c]linical 
research regarding the therapeutic benefits of cannabis (“marijuana”) has been almost non-
existent in the United States since cannabis was given Schedule I status in the Controlled 
Substances Act of 1970”). 
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The federal government’s Schedule I stranglehold is not a complete 
ban; but it has significantly hindered the development of meaningful 
widespread research. For example, only 11 marijuana studies were 
authorized from 2000 to 2009.57 To make matters worse, NIDA,58 which 
must approve all cannabis research,59 restricts all research to a single strain 
of research-grade pot grown only at the University of Mississippi. NIDA 
provides authorized labs only with what has been described as a 
“micronized powder” form of this Mississippi-grown cannabis.60 
Unsurprisingly, researchers regularly complain that this powdered pot is 
an extremely poor analog for the wide range of cultivated, dispensary-
available products.61 
If the research to date reveals anything about the pharmacology of 
marijuana, we know that it is extremely complex. Pot’s main 
psychoactive chemical is delta-9-tetrahydrocannabinol (“THC”), but it 
also contains over 500 other chemicals with virtually unknown properties 
and effects.62 Without a solid foundational understanding of pot’s 
chemical composition, we cannot reliably measure the impact of basic 
scientific variables including: (1) the ever-expanding variety of delivery 
methods (e.g. smoking, vaping, edibles); (2) THC and other chemical 
potency variations; (3) physiological and psychological distinctions 
 
 57. Id. 
 58. Mikos, supra note 16 at 1433–34. 
 59. In fiscal year 2017, the NIH through NIDA “supported 330 projects totaling 
almost $140 million on cannabinoid research.” NIH Research on Marijuana and 
Cannabinoids, NAT’L INST. ON DRUG ABUSE, http://bit.ly/2C51Gmf (last updated May 
2018); see also Estimates of Funding for Various Research, Condition, and Disease 
Categories (RDC), NAT’L INST. ON DRUG ABUSE (May 18, 2018), 
https://report.nih.gov/categorical_spending.aspx. 
 60. THE HEALTH EFFECTS OF CANNABIS, supra note 33, ch. 15 (noting that, “[b]ecause 
of restrictions on production and vicissitudes in supply and demand, federally produced 
cannabis may have been harvested years earlier, is stored in a freezer (a process that may 
affect the quality of the product).”). 
 61. Caleb Hellerman, Scientists Say the Government’s Only Pot Farm Has Moldy 
Samples—and No Federal Testing Standards, PBS NEWS HOUR (Mar. 8, 2017, 3:55 PM), 
https://to.pbs.org/2GcrJfp (citing researchers’ concerns that pot ordered for research 
purposes “didn’t resemble cannabis” and “didn’t smell like cannabis,” and that some 
“samples were contaminated with mold, while others didn’t match the chemical 
potency . . . requested for the study”); Tom Hesse, Weak Weed and Red Tape: Marijuana 
Research is Slow Going, CHRON. HIGHER EDUC. (Feb. 28, 2017), 
https://www.chronicle.com/article/Weak-WeedRed-Tape-/239328 (citing concerns that 
“the cannabis strain that Mississippi has been providing is so low in THC . . . it’s not really 
possible to do actual use-patterns analysis . . . . [N]o one uses that. Everyone’s been using 
really powerful stuff.”); Sara Reardon, Marijuana gears up for production high in US labs, 
519 NATURE 269, 269–70 (2015); Sarah See Stith & Jacob Miguel Vigil, Federal barriers 
to cannabis research, 352 SCIENCE 1182, 1182 (2016).  
 62. Hellerman, supra note 61; see also MARTIN BOOTH, CANNABIS: A HISTORY 5–6 
(2004) (noting that, “[o]f the approximately 460 known chemical constituents of cannabis, 
more than sixty have the molecular structure of a cannabinoid . . . .”). 
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between habitual and occasional users; (4) user age differences; (5) 
second-hand effects; and/or (6) drug and alcohol interactions. The paucity 
of the current evidence base has been specifically criticized by the WHO, 
which recently opined that “more research is needed on the basic 
neuropharmacology of THC and other cannabinoids.”63 
In this scientific evidence void, our continued reliance on copycat 
laws borrowed from regulations governing alcohol or other drugs (such as 
opioids) is inherently suspect. Different intoxicants have distinct chemical 
properties and effects, most notably alcohol’s steady metabolism rate 
(which provides lawmakers with an empirically accurate base for 
extrapolating an impairment timeline)64 and the chemical consistency of 
prescription narcotics. Cannabis impairment assessment, which I intend to 
address in a forthcoming companion article, is especially tricky because 
we have limited data on the measurement of cannabinoids in various 
bodily fluids, no scientific consensus on the correlation of cannabinoid 
levels to impairment effects (i.e., human judgment, motor coordination, 
and reaction time), and no agreement on valid roadside measurement 
methods or devices. 
D. Introduction to the Politics of Legalization 
Legalizing pot, before we have begun to understand its potential 
psychopharmacological and physiological effects, is a public health and 
policy problem because it is “counterintuitive to the mission of our 
governmental agencies.”65 To make evidence-based decisions, 
policymakers first need “clinical researchers to acquire safety and efficacy 
data on products in the marketplace.”66 But even accurate scientific 
information cannot always steer public policy in a climate of divisive and 
inconsistent party politics. As discussed below, the Obama and Trump 
administrations may have differed on the enforcement of criminal 
sanctions, but they both have ignored the recommendation of the 
American Medical Association to remove marijuana from Schedule I to 
permit clinical research and facilitate the development of new cannabis-
 
 63. Cannabis, WORLD HEALTH ORG., http://www.who.int/substance_abuse/ 
facts/cannabis/en/ (last visited Mar. 18, 2019) [hereinafter WHO, Cannabis]. 
 64. Marijuana Research: Frequently Asked Questions, UNIV. OF MISS., 
https://pharmacy.olemiss.edu/marijuana/ (last visited Mar. 18, 2019). 
 65. Summary of Request for Information (RFI) Regarding Varieties of Marijuana and 
Marijuana Products for Research, NAT’L INST. ON DRUG ABUSE, http://bit.ly/2Qxz3a0 (last 
updated Nov. 2016) [hereinafter NIDA, Summary of RFI]. 
 66. Id. 
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derived medicines.67 State legalization provides marijuana to the people, 
but does nothing to advance the science. 
The messy politics of marijuana science transcends the partisan 
divide. “Post-truth” America has an increasingly uncomfortable 
relationship with science, evidence, and facts. Stephen Colbert introduced 
the word “truthiness,” into the vernacular in 2005—deftly capturing the 
political zeitgeist of an American public increasingly “divided between 
those who think with their head and those who know with their heart.”68 
More recently, cognitive scientists Hugo Mercier and Dan Sperber suggest 
that facts are decreasingly important, not merely because human ability to 
reason is inherently flawed; but because we increasingly use reason 
principally to critique the ideas of others.69 Reason serves just two 
functions, “that of producing reasons for justifying oneself, and that of 
producing arguments to convince others.”70 The current perfect storm of 
scientific ignorance, empirical relativism, and (if Mercier and Sperber are 
correct) the diminished role of reason, impacts all law and science 
questions—from global climate change and environmental safety to 
intimate questions of reproductive health.71 Although legal marijuana may 
draw bipartisan support,72 voters’ and legislators’ common ground on a 
highly lucrative new local market does not demonstrate values-based 
bipartisan agreement or a shared commitment to evidence-based public 
policy. 
A truthiness approach to marijuana legalization also fits with our 
increasing about basic science. In surveys conducted over the past decade, 
Americans consistently reveal a shocking unfamiliarity with middle-
school level scientific facts and methods. Among adults, 53% do not know 
how long it takes for the earth to revolve around the sun, 41% believe that 
humans and dinosaurs lived together at the same time, and 47% cannot 
even roughly approximate how much of the earth’s surface is covered with 
 
 67. See COUNCIL ON SCI. & PUB. HEALTH, AM. MED. ASS’N, REP. NO. 3-I-09, USE OF 
CANNABIS FOR MEDICINAL PURPOSES 2 (2009), http://bit.ly/2B9CXeJ. 
 68. SOPHIA A. MCCLENNEN, COLBERT’S AMERICA: SATIRE AND DEMOCRACY 123 
(2011) (ebook). 
 69. HUGO MERCIER & DAN SPERBER, THE ENIGMA OF REASON 7–11 (2017). 
 70. Id. at 8. 
 71. Andrew Sullivan, When Two Tribes Go to War, N.Y. MAG. (Feb. 2, 2018, 9:35 
AM), https://nym.ag/2PuITUV. 
 72. Astead W. Herndon, Meet Colorado’s New Single-Issue Voters: The Cannabis 
Community, N.Y. TIMES (June 25, 2018), https://nyti.ms/2LaxgSo (“In the 2018 midterm 
elections, [cannabis] industry leaders are hoping that the spread of marijuana legalization 
will lead to the birth of a new single-issue voter: People who, like some Medicare recipients 
or gun owners, are motivated to cast ballots based on the benefits they have received or 
fears about any government rollback of access.”). 
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water.73 Under these circumstances, it is not surprising that marijuana 
proponents appear uninterested in the science. Scientific ignorance and 
disinterest, a growing disinclination to question our own beliefs, and 
instant access to all sorts of scientific-sounding information on the internet 
are a toxic combination that is “dramatically reshap[ing] our relationship 
to the world of knowledge” by “unmoor[ing] information from the context 
required to understand it.”74 The regular consumption of partisan 
information (whether on Facebook, Breitbart, or CNBC) without debate 
or context has been shown to exacerbate critical reasoning deficits on all 
evidence-based questions—even those seemingly unrelated to party 
politics.75 
E. Why the Science and Politics of Legal Pot Matters 
According to the philosopher Susan Haack, “[t]he core 
epistemological values of science are rooted in the central, defining 
concern of inquiry generally: finding things out.”76  Science invariably 
works within society, but when the surrounding culture works to 
“undermine the norms of evidence sharing and respect for evidence, or . . . 
erode or compromise them, the integrity of science comes under threat.”77 
But even if we could overcome truthiness obstacles, because the marijuana 
movement is driven by users and profit-seeking legislators, proponents 
have no reason to advocate for better scientific research. If medical and/or 
psychological risks are real, these will only create impediments. But the 
paucity of the medical evidence is a critical legal and policy problem. 
Without more comprehensive information on the health benefits and 
palliative effects of marijuana, doctors, lawmakers, voters, and consumers 
cannot make scientifically sound decisions. The current “lack of evidence-
based information on the health effects of cannabis and cannabinoids 
 
 73. American Adults Flunk Basic Science, SCIENCEDAILY (Mar. 13, 2009), 
http://www.sciencedaily.com/releases/2009/03/090312115133.htm. 
 74. SETH MNOOKIN, THE PANIC VIRUS 5–8 (2011) (describing the promulgation of the 
increasingly popular and dangerous myth that MMR vaccines cause autism). 
 75. Jeff Cirillo, Warren, Gardner Unveil Marijuana Bill Easing Federal Enforcement, 
ROLL CALL (June 7, 2018, 2:11 PM), http://bit.ly/2RN0KrY. But see ANDREW GUESS ET 
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 76. Susan Haack, The Integrity of Science: What it Means and Why it Matters, 11 
COLECÇÃO BIOÉTICA 9, 10 (2006) (Portugal), http://perma.cc/B9M7-2AD2.  
 77. Id. 
 416 PENN STATE LAW REVIEW Vol. 123:2 
[itself] poses a public health risk”78 with significant and immediate legal 
and regulatory ramifications. 
This Article tackles the science and politics of legal pot. As an inquiry 
into basic principles, it specifically rejects the currently faddish 
“unintended consequences” legal academic lens. A quick look at Westlaw 
reveals that, in this context, these unintended consequences approach has 
spawned myriad academic “what if” prognostications relating to 
regulatory problems of varying interest and importance (e.g., employment, 
expungement, land use, trademark and zoning problems). This Article 
refocuses on the fundamental legal, political and practical meaning of 
increasing public access to a chemical substance we have not, and 
currently cannot, properly research. The goals are to explore the basic 
science of marijuana, to explain why gathering more evidence is essential 
to a legitimate regulatory scheme, and to expose the current legal and 
political obstacles to better science and better public health policy 
decisions. 
The Article is organized as follows. Part I explains the cannabis 
basics—describing what marijuana is, where it comes from, and how it is 
used medically and recreationally. Part II provides a user-friendly guide to 
the current state-of-the-science of marijuana highlighting the Rumsfeldian 
“known unknowns” and “unknown unknowns,”79 including marijuana’s 
medical potential and its short and long-term psychopharmacological 
effects. Part III explores the evolving law of marijuana—briefly 
examining the relevant Constitutional questions including federal-state 
preemption, the Commerce Clause, the Tenth Amendment’s Anti-
Commandeering doctrine, and congressional funding power. Finally, Part 
IV anticipates the future of legal pot and predicts that the current 
simulacrum of bipartisanship does not reflect actual shared understanding 
and cannot insulate marijuana from our increasingly tribalized and 
scientifically ignorant approach to all evidence-based questions of law and 
policy. 
II.  THE BASICS 
A. The History of Marijuana 
According to the National Institute on Drug Abuse [NIDA], 
Marijuana—also called weed, herb, pot, grass, bud, ganja, Mary Jane, 
and a vast number of other slang terms—is a greenish-gray mixture of 
the dried flowers of Cannabis sativa [and] some people smoke 
 
 78. THE HEALTH EFFECTS OF CANNABIS, supra note 34, ch. 15. 
 79. David A. Graham, Rumsfeld’s Knowns and Unknowns: The Intellectual History 
of a Quip, THE ATLANTIC (Mar. 27, 2014), http://bit.ly/2LdA553. 
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marijuana in hand-rolled cigarettes called joints; in pipes, water pipes 
(sometimes called bongs), or in blunts (marijuana rolled in cigar 
wraps).80 
Cannabis is the generic name for hemp. The precise etymology of 
“marijuana” is unknown, but it has been traced to an Aztec slang word for 
“brothel.”81 
The geographic origin of marijuana is also unknown, although most 
studies suggest that it probably evolved in central Asia.82 Cannabis use has 
a very long history, and we can (somewhat) reliably trace its origins to the 
ancient world. A 2017 meta-analysis of marijuana’s history and 
pharmacology reports that cannabis was first described “more than 5,000 
years ago in what is now Romania,” but the first direct evidence of use 
(THC found in ashes) dates to 400 A.D.83 Cannabis use in the U.S. began 
during the 19th and early 20th centuries. Marijuana was legal to grow and 
consume until the 1910s, when states first began criminalize the drug.84 
But starting in the 1930s, “every state . . . banned the cultivation, 
distribution, and possession of marijuana for non-medical purposes.”85 
The first federal restrictions appeared in the 1937 Marihuana Tax 
Act.86 Additional efforts to control marijuana were included in the Boggs 
and Narcotic Control Acts of 1951 and 1956 and in the 1970 Controlled 
Substances Act (“CSA”).87 As noted above, a half century ago the CSA 
classified marijuana as a Schedule I drug based on a congressional finding 
that pot has no possible acceptable medical use. This legislative 
presumption has precluded robust scientific research on marijuana’s 
effects and continues (confusingly) to make pot illegal under federal law, 
in every state where it has been legalized. 
Marijuana was initially criminalized for highly problematic political 
and social reasons. The racist and xenophobic origins of the mid-twentieth 
century marijuana prohibition movement are well documented.88 Early 
cannabis criminalization coincided with an influx of Mexican immigrants 
 
 80. NIDA, MARIJUANA, supra note 48, at 5.  
 81. Id. 
 82.  BOOTH, supra note 62, at 2–3.  
 83. Bridgeman et al., supra note 50, at 180. 
 84. Erwin Chemerinsky et al., Cooperative Federalism and Marijuana Regulation, 62 
UCLA L. REV. 74, 81 (2015). 
 85. Robert A. Mikos, On the Limits of Supremacy: Medical Marijuana and the States’ 
Overlooked Power to Legalize Federal Crime, 62 VAND. L. REV. 1421, 1427 (2009). 
 86. Id. 
 87. Id.; Chemerinsky et al., supra note 84, at 80 (“It has been well documented that 
the move to regulate marijuana was motivated in large part by racism and xenophobia.”). 
 88. Alex Halperin, Marijuana: Is It Time to Stop Using a Word With Racist Roots?, 
THE GUARDIAN (Jan. 29, 2018, 5:00 AM), http://bit.ly/2Quxidy. 
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to the U.S. at the turn of the last century.89 As Harry Anslinger, 
Commissioner of the Federal Bureau of Narcotics from 1930-1962, 
infamously asserted in a tirade against the drug: “There are 100,000 total 
marijuana smokers in the US, and most are Negroes, Hispanics, Filipinos 
and entertainers. Their Satanic music, jazz and swing result from 
marijuana use. This marijuana causes white women to seek sexual 
relations with Negroes, entertainers and any others.”90 This shameful past 
has prompted some legalization proponents to propose that the name 
“marijuana” be abandoned to better distance the drug from its shameful 
past.91 
Modern cannabis originated in the 1970s in California “when 
professional breeders began to select the most potent, THC-rich plants for 
the first time.”92 Before modern cultivation, most marijuana was imported 
as “hashish resin, made of mixed populations of plants from parts of Asia, 
Africa, and the Caribbean, containing varying amounts of both CBD and 
THC.”93 A half-century ago, almost all of the marijuana consumed in the 
United States was imported, but over the past few decades, this has 
changed dramatically.94 Today we see a near-complete shift to American-
grown marijuana, with California growing 80% of the cannabis consumed 
across the U.S.95 The 50 year-old movement towards domestic marijuana 
coincides with significant horticultural and genetic advances as U.S. 
growers began “selectively breeding THC-rich plants . . . in the quest to 
make ever stronger cannabis.”96 These efforts have been wildly successful, 
resulting in scientific consensus that deliberate new horticultural methods 
have caused a significant rise in THC levels in cultivated marijuana.97 
B. Modern Marijuana 
Marijuana is currently available in a wide variety of strains and 
incorporated into a range of products. Different cannabis strains “have 
 
 89. Alyssa Pagano, The Racist Origins of Marijuana Prohibition, BUS. INSIDER (Mar. 
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 96. Ireland, supra note 92; see also Brady, supra note 95. See generally Zlatko 
Mehmedic et al., Potency Trends of Δ9-THC and Other Cannabinoids in Confiscated 
Cannabis Preparations from 1993 to 2008, 55 J. FORENSIC SCI. 1209 (2010). 
 97. Mehmedic et al., supra note 96, at 1216. 
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varying chemical components.”98 In addition to different strains, 
marijuana is also available in a variety of forms, including sinsemilla, an 
especially potent variety derived from specially tended female plants, and 
concentrated resins such as hash oil, budder, and shatter.99 For-profit 
marijuana analytics companies currently help sellers and buyers 
differentiate among strains and products. According to a recent Wired 
magazine investigative report, pot labs now use “analytical chemistry” 
(and crowd-sourced reviews) to “quantify 27 of the most prominent of 
these flavorful, experience-defining molecules.”100 
Legitimate cannabis genetic research could have significant 
implications for better understanding pot’s medicinal and palliative 
potential and its psychopharmacological effects. But horticultural 
geneticists complain that their work is impeded by pot’s Schedule I status. 
Unlike “[e]very other commercially important agricultural plant in the 
world [which] has had a ton of research done on it,” marijuana “has so 
much variation, and nobody knows what that variation’s all about.”101 
Plant biologists cannot research the basic bases for genetic differences, 
which is “what you need if you plan to breed scientifically, to enhance the 
qualities the market might pay for,”102 despite the fact that more genetic 
data would also be useful for medical research because different chemicals 
“ameliorate clinical symptoms differently.”103 Ironically, cannabis 
cultivators seeking solely to enhance THC psychoactivity have 
compounded these problems. By crossbreeding to achieve the goal of 
stronger marijuana, modern marijuana farmers inadvertently create 
genetic sequencing complications by developing strains with multiple 
copies of the gene that synthesizes THC.104 
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C.  How Does Marijuana Work? 
1.  Cannabinoids 
The cannabis plant “produces a resin containing psychoactive 
compounds called cannabinoids, in addition to other compounds found in 
plants, such as terpenes and flavonoids.”105 In the cannabis plant, “[t]he 
highest concentration of cannabinoids is found in the female flowers.”106 
More specifically, “cannabinoid” describes “a pharmacological class 
of about 60 naturally occurring compounds (phytocannabinoids) found in 
plants of the genus Cannabis (i.e. marijuana and hemp) and structurally 
related synthetic analogues.”107 Cannabinoids are biochemically 
significant because these are the “chemicals that act on the brain’s 
cannabinoid receptors, part of a system that regulates a variety of 
physiological processes including pain sensation, mood, memory and 
appetite.”108 To date, over 100 cannabinoids have been identified.109 Pot’s 
main psychoactive cannabinoid is THC.110 THC levels have varied widely 
over time and continue to vary among different products. For example, 
fifteen years ago “the average THC content in weed was about 3 percent 
by weight.”111 Today, THC “levels top out at a whopping 37 percent.”112 
In addition to THC, pot “contains more than 500 other chemicals, 
including more than 100 compounds that are chemically related to 
THC.”113 
The basic biochemical explanation for how THC affects the brain 
begins with cannabinoid receptors, which are located “in many key 
regions, including the amygdala (responsible for processing memory and 
emotional reactions) as well as the basal ganglia and cerebellum 
(responsible for motor control, among other things).”114 Cannabinoid 
receptors also exist throughout the brain and body within cell membranes 
and control a host of physiological and psychological functions.115 THC 
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has psychoactive effects because it alters the chemical messages sent to 
specific brain areas, including those that “regulate appetite, memory, fear 
extinction, motor responses, and posture such as the hippocampus, basal 
ganglia, basolateral amygdala, hypothalamus, and cerebellum.”116 
2.  The Endocannabinoid System 
Although THC does not occur naturally in the body, THC acts 
directly on the entire endocannabinoid system (“ECS”), which is 
comprised of “cannabinoid receptors along with ‘endogenous 
cannabinoids (endocannabinoids)[] and the enzymes responsible for the 
synthesis and degradation of the endocannabinoids.”117 Because the 
chemical structure of THC is very similar to the brain 
chemical anandamide, which binds to THC receptors,118 the body 
‘recognize[s] THC and [allow it] to alter normal brain communication.”119 
These alterations are not just psychoactive, but can include effects on 
appetite, pain, motor-learning, and inflammation because the ECS “is a 
widespread neuromodulatory system that plays important roles in central 
nervous system [(CNS)] development, synaptic plasticity, and the 
response to endogenous and environmental insults.”120 Endocannabinoids, 
which our bodies make naturally, ”function as neurotransmitters because 
they send chemical messages between nerve cells (neurons) throughout 
the nervous system. They affect brain areas that influence pleasure, 
memory, thinking, concentration, movement, coordination, and sensory 
and time perception.”121 THC is considered an exogenous cannabinoid 
(phytocannabinoid) because the body does not make it, but THC has a 
similar ability to stimulate neural receptors.122 
 
[R]ecent work has provided evidence that the endocannabinoid system . . . isn’t 
exclusive to the brain. It is present everywhere in the body that scientists have 
looked: the heart, liver, pancreas, skin, reproductive tract, you name it. And 
disrupted endocannabinoid signaling has been associated with many disorders, 
including diabetes, hypertension, infertility, liver disease, and more. “There is so 
much that’s still unknown about this system. It looks to be regulating every 
physiological system in the body.” 
Id. (quoting Nick DiPatrizio, Assistant Professor at U.C. Riverside, School of Medicine). 
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 117. Hui-Chen Lu & Ken Mackie, An Introduction to the Endogenous Cannabinoid 
System, 79 BIOLOGICAL PSYCHIATRY 516, 516 (2016). 
 118. NIDA, MARIJUANA, supra note 48, at 9. 
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 120. Lu & Mackie, supra note 117, at 516. 
 121. NIDA, MARIJUANA, supra note 48, at 9. 
 122. See Flora E. Kovacs et al., Exogenous and Endogenous Cannabinoids Suppress 
Inhibitory Neurotransmission in the Human Neocortex, 37 NEUROPSYCHOPHARMACOLOGY 
1104, 1104 
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D.  How is Marijuana Used? 
1.  Cannabis Products 
Marijuana is—roughly speaking—used for two different purposes: 
(1) medicinal treatment and palliative care for a wide range of disorders 
and conditions, and (2) fun. 
Medicinal marijuana users and recreational users typically fit 
different profiles. Medical users are often older (typically middle-aged) 
and are frequently diagnosed with debilitating illnesses (such as cancer), 
neurological or musculoskeletal problems, or chronic infections.123 
Marijuana’s medical potential is discussed in more detail below, but access 
to both medical and recreational marijuana is limited to those who can 
afford to pay out of pocket, because even in states where medical 
marijuana has been legalized, marijuana is a cash-only business with no 
possibility of insurance coverage. 
Medicinal and recreation cannabis is consumed in a variety of ways. 
These include smoking or inhaling from cigarettes (joints), pipes 
(bowls), water pipes (bongs, hookahs), and blunts (cigars filled with 
cannabis); eating or drinking food products and beverages; or 
vaporizing the product. These different modes are used to consume 
different cannabis products, including cannabis “buds” (dried cannabis 
flowers); cannabis resin (hashish, bubble hash); and cannabis oil 
(butane honey oil, shatter, wax, crumble).124 
The dizzying array of marijuana consumption options can have a distinct 
psychopharmacological impact. 
2.  Consumption Methods 
Whether one uses pot as a medicine or for recreation, the choice of a 
particular method of marijuana consumption “impact[s] the onset, 
intensity, and duration of psychoactive effects; effects on organ systems; 
and the addictive potential and negative consequences associated with 
use.”125 NIDA reports that vaping is increasingly popular.126 This may be 
attributable to the fact that “[v]aporization provides effects similar to 
smoking while reducing exposure to the byproducts of combustion and 
possible carcinogens and decreasing adverse respiratory syndromes.”127 
 
 123. See Alice Robb, This Is What the Average Medical Marijuana User Looks Like, 
NEW REPUBLIC (Jan. 9, 2014), http://bit.ly/2UIFshh. 
 124. THE HEALTH EFFECTS OF CANNABIS, supra note 33, at 50. 
 125. Bridgeman et al., supra note 50, at 182. 
 126. NIDA, MARIJUANA, supra note 48, at 5. 
 127. Bridgeman et al., supra note 50, at 182. 
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When cannabis is smoked or vaped, THC rapidly diffuses to the brain, 
eliciting a perceived high within seconds or minutes, reaching a peak after 
about 30 minutes, and subsiding within 2 to 3 hours.128 “‘Dabbing,’ a term 
for flash-vaporizing butane hash oil-based concentrates, has been reported 
to offer a different and stronger intoxicating effect than smoking/
vaping.”129 Whether marijuana is smoked, vaped, or dabbed, “THC and 
other chemicals in the plant pass from the lungs into the bloodstream, 
which rapidly carries them throughout the body to the brain. The person 
begins to experience effects almost immediately.”130 For users seeking a 
quick biochemical response, these are preferred consumption methods. 
Marijuana consumed in foods or beverages, while also popular, will 
produce a very different effect. The high is typically delayed—usually 
appearing after 30 minutes to 2 hours—because the intestine must absorb 
the drug transport it to the liver.131 Eating or drinking marijuana can also 
impact dosing. Edibles “deliver[] significantly less THC into the 
bloodstream than smoking [or vaping/dabbing] an equivalent amount of 
the plant. Because of the delayed effects, people may inadvertently 
consume more THC than they intend to.”132 According to NIDA, variable 
potency rates and the delayed effect of ingestion are common causes of 
overconsumption.133 The effects of marijuana will typically last a few 
hours, although detectable amounts of THC can remain in the body for 
days or even weeks.134 However, the choice of a particular consumption 
method can alter the “duration of the psychotropic effects, the effects on 
organ systems, and the addictive potential and negative consequences 
associated with its use.”135 
Pharmacokinetic research, which explores the absorption, 
distribution, metabolism, and excretion of drugs, is a generally 
complicated field.136 Confounding factors specific to marijuana research 
include: (1) problems created by low concentrations of relevant chemical 
constituents; (2) the rapid and extensive metabolism of THC in the body; 
and (3) the complexity of separating different compounds of interest from 
other compounds and biological tissues.137 Research into the specific 
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 129. THE HEALTH EFFECTS OF CANNABIS, supra note 33, at 51. 
 130. NIDA, MARIJUANA, supra note 48, at 8. 
 131. THE HEALTH EFFECTS OF CANNABIS, supra note 33, at 51. 
 132. NIDA, MARIJUANA, supra note 48, at 8; see also Bridgeman et al., supra note 51, 
at 182. 
 133. NIDA, MARIJUANA, supra note 48, at 8. 
 134. Id. 
 135. THE HEALTH EFFECTS OF CANNABIS, supra note 33, at 51. 
 136. See generally Marilyn A. Huestis, Human Cannabinoid Pharmacokinetics, 4 
CHEMISTRY & BIODIVERSITY 1770 (2007) (illustrating the complexity of cannabinoid 
pharmacokinetics).  
 137. See Bridgeman et al., supra note 50, at 182. 
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pharmacokinetics of marijuana is further complicated by the many 
different available methods of consumption.138 For example, we know that 
the “[i]nhaled THC causes a maximum plasma concentration within 
minutes, psychotropic effects start within seconds to a few minutes, reach 
a maximum after 15-30 minutes, and taper off within 2-3 hours.”139 In 
contrast, psychotropic effects of orally ingested marijuana manifest within 
“30-90 minutes, reach their maximum after 2-3 hours and last for about 4-
12 hours, depending on dose and specific effect.”140 The increasing array 
of consumption options poses challenges to the accuracy, consistency, and 
future validity of any pharmacokinetic findings. 
The psychoactive effects of marijuana, which are a factor for both 
medicinal and recreational users, also vary wildly based on the individual 
consumer. Common reported experiences “include heightened sensory 
perception (e.g., brighter colors), laughter, altered perception of time, and 
increased appetite.”141 In anecdotal reports compiled by NIDA, many 
people also feel “a pleasant euphoria and sense of relaxation,” although 
some pot users instead report feeling “anxiety, fear, distrust, or panic.”142 
There are also reports of users who “experience an acute psychosis, which 
includes hallucinations, delusions, and a loss of the sense of personal 
identity[,]” especially after taking larger marijuana doses.143 A recent 
study published in the Journal of Child Psychology and Psychiatry 
suggests the possibility that some adolescent marijuana users may 
experience “psychotic-like experiences” including perceptual 
abnormalities and delusional thoughts.144 However, NIDA reports that 
“unpleasant but temporary reactions [to marijuana] are distinct from 
longer-lasting psychotic disorders, such as schizophrenia . . . .”145 
3.  Marijuana Use for Creativity 
Many recreational use proponents cite anecdotal evidence of 
marijuana’s positive effect on creativity. For example, television 
personality Bill Maher, a long-time cannabis aficionado, posits that 
marijuana is linked to creativity: “[I]f I’m staring at the blank computer 
screen sober, I’m thinking, ‘Uh, I don’t want to start this, it’s an 
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ASSIGNMENT!’ Then, as soon as I’m high, which takes about three 
seconds, it’s, ‘Oh, this is fun! This isn’t an assignment. It’s a GAME.’”146 
Discussions of marijuana’s inspirational potential are also often supported 
by a list of well-known artist habitués. A quick online search suggests that 
pot has been the drug of choice for a wide range famous creative people 
including jazz, rock, folk, country, rap and hip-hop musicians (Louis 
Armstrong, Bob Dylan, the Beatles, Bob Marley, Willie Nelson, Jerry 
Garcia, Snoop Dogg, Jay-Z, Lady Gaga, and Wiz Khalifa) and various 
movie stars (Woody Harrelson, Brad Pitt, and Matthew McConaughey). 
The three most recent former presidents (Barack Obama,147 George W. 
Bush,148 and Bill Clinton149) each admitted to (or hinted at) marijuana use, 
yet the only artist,150 has never cited marijuana as source of creative 
inspiration. 
Recent research suggests that the link between pot and creativity 
could be more than anecdotal. Dr. Alice Flaherty, a Harvard neurologist, 
has explored the effects of both alcohol and marijuana on creativity.151 Her 
research demonstrates that alcohol inhibits brain activity, although the 
disinhibiting effects of alcohol may reduce some obstacles to creativity—
including self-criticism.152 According to Dr. Flaherty: “One of the 
important aspects of creative attention is that it’s often hyper-focused in 
certain ways—and yet you have to be able to pay attention to relevant 
things that you’re not expecting. Marijuana seems to help that focus.”153 
However, a contradictory 2017 study concluded that although cannabis 
users may “appear to demonstrate enhanced creativity, these effects are an 
artifact of their heightened levels of openness to experience.”154 At the 
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moment, most of the reports linking marijuana to creativity remain 
anecdotal. 
4.  Cannabis Connoisseurship 
As recreational marijuana has become more popular, a cottage 
industry of cannabis connoisseurship has developed. Since 2014, the 
Denver Post has employed a full-time marijuana editor, whose popular 
website (www.thecannabist.co) reviews a wide variety of cannabis strains 
and accouterments.155 Distinct cannabis character (i.e., flavor, smell, 
effect, duration) is attributed to the “entourage effect,” the chemical 
reaction among the hundreds of chemicals including cannabinoids, 
terpenes, and flavonoids.156 The cannabis industry promotes the idea that 
such entourage effects translate into psychopharmacological differences. 
“In the old days, you’d smoke what you could get . . . . Now, there’ll be 
so much diversity in strains that you’ll be able to pick the exact high you 
want.”157 Presumably, these claims also account for differences in 
dispensary prices. 
Unsurprisingly, there is little science to support cannabis distinction 
claims. In fact, “many scientists see the whole [connoisseurship] thing as 
a pipe dream. The idea that botanical marijuana creates a synergistic 
chemical effect, fingerprinting the experience with ‘uplifting’ or ‘relaxing’ 
or ‘munchy’ notes, is highly contentious.”158 Designer pot has captured the 
public imagination, with dispensaries “listing and advertising various 
cannabinoid ratios and providing detailed terpene profiles in certain strains 
and products.”159 Claims of psychoactive effect variations linked to 
different cannabis strains or varieties, like claims of medical benefits, have 
never been scientifically validated because “[d]ouble-blind clinical trials, 
the gold standard for research studies in medicine, have never been 
conducted to investigate the effects of marijuana’s terpenes or its 
cannabinoids other than THC.”160 Even THC, as discussed in more detail 
herein, has been subjected to only the most preliminary scientific testing. 
 
 155. See THE CANNABIST, https://www.thecannabist.co/ (last visited Mar. 18, 2019) 
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III.  THE SCIENCE OF POT 
A. State-Defined Diseases and Conditions 
In the 30 states that have enacted medicinal marijuana statutes, 
lawmakers typically specify eligible diseases and conditions. These lists 
run the gamut. Alabama, one of the most restrictive states, legalized 
cannabis only for use in state-sponsored clinical research trials aimed at 
treating severe, debilitating epileptic conditions.161 Michigan, in contrast, 
recently became one of the most permissive states when it expanded its 
medical authorization to 22 different conditions including: PTSD, Cancer, 
Glaucoma, HIV, AIDS, Hepatitis C, Amyotrophic Lateral Sclerosis, 
Crohn’s disease, agitation of Alzheimer’s disease, Nail Patella, Autism, 
chronic pain, Colitis, Inflammatory Bowel Disease, Obsessive 
Compulsive Disorder, Parkinson’s, Rheumatoid Arthritis, spinal cord 
injury, Tourette’s syndrome, and Ulcerative Colitis.162 
In the more permissive states, a specific diagnosis may not be 
required to obtain legal medical cannabis. For example, in addition to a 
long list of eligible diseases and conditions, California includes a catchall 
provision to accommodate: 
Any other chronic or persistent medical symptom that either: (A) 
Substantially limits the ability of the person to conduct one or more 
major life activities as defined by the Americans with Disabilities Act 
of 1990 . . . . (B) If not alleviated, may cause serious harm to the 
patient’s safety or physical or mental health.163 
Like California, Michigan has legalized medicinal marijuana to treat any 
“chronic or debilitating disease or medical condition . . . that produces . . . 
cachexia or wasting syndrome; severe and chronic pain; severe nausea; 
seizures (including but not limited to those characteristic of epilepsy); or 
severe and persistent muscle spasms (including but not limited to those 
characteristic of multiple sclerosis or arthritis).”164 As new states expand 
their qualifying conditions to include more diseases/conditions and 
generalized pain and symptomology, more people will start using 
marijuana, despite the fact that half-century old obstacles to researching 
marijuana’s treatment or palliative efficacy will likely remain in place. 
 
 161. See UAB Cannabidiol Program, UNIV. OF ALA. BIRMINGHAM SCH. OF MED., 
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B.  Obstacles to Medical Research 
1.  Research-Grade Pot 
Since the 1970 enactment of the CSA, the federal government has 
strictly regulated scientific marijuana research.165 As noted above, pot’s 
Schedule I status combined with NIDA regulations limiting researchers to 
the University of Mississippi grown “micronized powder” cannabis, have 
stymied robust scientific inquiry.166 NIDA’s research-grade marijuana “is 
less potent than the pot offered at dispensaries”167 because NIDA limits 
distribution to “low-THC, zero-CBD strains.”168 According to one 
Colorado-based PTSD researcher, local dispensaries offer products with 
THC levels as high as 30%169 and although NIDA claims to provide a 
product with 13% THC levels, independent testing reveals that NIDA’s 
research-grade marijuana has inconsistent THC levels, which are often 
lower than 13%.170 This complicates efforts to research the effects of the 
marijuana products people actually use. The NIDA marijuana “available 
through the federal system do[es] not sufficiently reflect the variety of 
products used by consumers, [so] research conducted using cannabis 
provided by NIDA may lack external validity.”171  
In addition to lower THC levels, research-grade cannabis is 
chemically distinct from medical and recreational “whole-plant marijuana, 
which contains hundreds of active ingredients with complicated 
synergistic and inhibitory interactions.”172 NIDA marijuana also “differs 
from other products offered at dispensaries.”173 
For years, “there has been an effort to petition the government to 
expand and improve the supply of research cannabis, as researchers and 
experts complain about not only the quantity of cannabis grown for 
research purposes, but also its quality and the diverse array of potency, 
chemical composition (cannabinoid profiles), and vehicles of consumption 
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(whole flower, vaporizers, oils, tinctures, etc.).”174 Today, “cannabis oil is 
popular,” but research on oil cannot be conducted “because the NIDA 
supply has not yet been trialed in humans . . . [and] the FDA will say it’s 
a ‘novel molecular entity’.”175 Federal research constraints also make it 
“difficult for researchers who want to look at newer delivery systems”176 
including “so-called edibles that are eaten like snacks.”177 
2.  Bureaucratic Hurdles 
Investigators seeking to conduct marijuana research also encounter 
many bureaucratic and financial hurdles. Specifically, U.S. laboratories 
seeking to study cannabis 
must navigate a series of review processes that may involve the 
National Institute on Drug Abuse (NIDA), the U.S. Food and Drug 
Administration (FDA), the U.S. Drug Enforcement Administration 
(DEA), institutional review boards, offices or departments in state 
government, state boards of medical examiners, the researcher’s home 
institution, and potential funders.178  
Funding is another common research barrier because “without adequate 
financial support, cannabis research will be unable to inform health care 
or public health practice or to keep pace with changes in cannabis policy 
and patterns of cannabis use.”179 
To date, NIDA scientists have conducted the majority of cannabis 
research, but federal allocation of research funds has the power to skew 
the direction of inquiry. For example, in 2015 “only 16.5 percent 
($10,923,472) of NIDA’s spending on cannabinoid research supported 
studies investigating therapeutic properties of cannabinoids”180 with the 
remaining 83.5% allocated to risk assessment research. It is possible, but 
far from certain, that the current massive shift to greater legal medicinal 
and recreational marijuana use could eventually provide an increased 
evidence base of its effects provoking the federal government to remove 
current research obstacles.  A more balanced investigatory approach by 
NIDA could yield a more comprehensive picture of potential health costs 
and benefits. However, given our current domestic policies, some of this 
new data may come from abroad. 
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3.  Help from Abroad 
Marijuana’s Schedule I status only limits domestic research. Because 
marijuana proponents have not, and likely will not, advocate for removing 
marijuana from Schedule I, we may need to rely on research conducted in 
other countries to inform U.S. policymaking. For example, Canada has a 
national Centre on Substance Use and Addiction [CCSUA], which “was 
created by Parliament to provide national leadership to address substance 
use in Canada. . . . [and] produce guidance for decision makers by 
harnessing the power of research, curating knowledge and bringing 
together diverse perspectives.”181 
In August 2017, the CCSUA issued a National Research Agenda on 
the Health Impacts of Non-Medical Cannabis Use.182  This national 
research agenda “defines important areas for cannabis research and 
identifies priorities for those working in the field.”183  These steps include 
the following:  (1) “identify[ing] current knowledge and research gaps 
related to the health effects of non-medical cannabis use;”  (2) 
“identify[ing] existing data sources that can augment available data and 
knowledge in this area;”  (3) “prioritiz[ing] the short-, medium- and long-
term opportunities for research on the health effects of non-medical 
cannabis use;”  and (4) discussing opportunities for collaboration among 
researchers and tangible next steps for moving forward with the research 
agenda.”184 
In Spain, the Observatorio Español de Cannabis Medicinal (an 
organization of cannabis scientists) sponsors an annual conference. 185 
During this conference, scientific research on topics including cancer and 
cannabis, pain and cannabis, and cannabis analytics were presented.186 
In the future, overseas labs may provide useful scientific research, 
but with marijuana consumption rates rising rapidly, U.S. researchers are 
at a significant disadvantage.  Over the past half century, federal 
restrictions have ensured that “[c]linical research regarding the therapeutic 
benefits of cannabis (“marijuana”) has been almost non-existent in the 
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United States.”187  As one epilepsy researcher summarized the global 
problem, people can easily buy and use a huge selection of marijuana 
products, but U.S. scientists cannot investigate “the safety, efficacy, and 
dosing of artisanal preparations available from dispensaries . . . and online 
sources.”188  This can lead to absurd results. In one laboratory “[t]he DEA 
visited and determined that we had to do more to bolt down the locked 
freezer,” but it was “kind of comical, with all of these medical marijuana 
dispensaries scattered around town, sitting in my office and talking about 
everything we had to do to get a small amount of THC, cannabidiol, and 
cannabinol – 400 milligrams.”189 
4.  The Federal Response 
NIDA is well aware of researchers’ concerns. In response to a 2016 
NIDA Request for Information, scientists across the country raised the 
following specific problems: (1) the lack of marijuana strains and products 
reflecting the diversity of products available in state dispensaries; (2) the 
lack of potency (i.e., marijuana with a higher THC content would better 
represent available products); (3) the small number and variety of 
marijuana chemotypes which precluded research into cannabinoids other 
than THC, terpenes, and flavonoids; (4) the lack of access to common 
marijuana strains (e.g., “those characterized as ‘indica’, ‘sativa’, and 
‘hybrid’”); and (5) the poor quality of placebo marijuana, which “does not 
smell, taste, or look like regular marijuana and thus does not serve as an 
effective placebo.”190 In an apparent response issued in August 2016, the 
DEA announced that it would expand its marijuana cultivation program to 
allow other growers to apply.191 But in November 2016 (after the DEA 
received 26 new site applications from potential pot growers), then U.S. 
Attorney General Jeff Sessions reversed course.192 To date, no additional 
marijuana cultivation sites have been federally approved. 
 
 187. Webb & Webb, supra note 56, at 109.  
 188. Brooke K. O’Connell et al., Cannabinoids in Treatment-Resistant Epilepsy: A 
Review, 70 EPILEPSY & BEHAV. 341, 341 (2017); see also Chen, supra note 156 (quoting 
Margaret Haney, a neurobiologist at Columbia University and cannabis researcher: “I 
would love to do a study comparing strains . . . . I would love to directly compare but I’m 
unable to work with any marijuana on the street or in dispensaries.”).  
 189. Wells, supra note 98.  
 190. NIDA, Summary of RFI, supra note 65.  
 191. See Hudak & Stenglein, supra note 174. 
 192. See id. (opining that this decision was based solely on personal “ideological 
biases” and the Attorney General’s “absolute aversion” to all forms of marijuana, observing 
that the Attorney General’s views are inconsistent with the views of President Trump, and 
asking that the Attorney General “listen[] to the experts around him who understand the 
needs of the medical research community,” “get[] out of the way of the free conduct of 
medical research,” and “stop[] coming between patients and answers to important medical 
questions.”).  
 432 PENN STATE LAW REVIEW Vol. 123:2 
C.  What We Know So Far 
1. Recent Global Meta-Analyses 
 a.  The National Academies of Sciences, Engineering, 
and Medicine 
In 2017, the National Academies of Sciences, Engineering, and 
Medicine (“NASEM”) published a four hundred and sixty-eight page 
report entitled: The Health Effects of Cannabis and Cannabinoids: The 
Current State of Evidence and Recommendations for Research.193 The 
NASEM report provides a meta-review of extant research into the health 
effects and health risks of cannabis and cannabis-derived products.194 The 
NASEM conducted an extensive search of literature databases “giving 
primacy to recently published systematic reviews (since 2011) and high-
quality primary research that studied 1 or more of 11 groups of health 
endpoints.”195 The health “endpoints” explored by the NASEM included a 
comprehensive analysis of potential therapeutic effects for a variety of 
medical and mental health diseases and conditions.196 The NASEM’s 
aggregation of health endpoints reflects the research conducted to date on 
marijuana’s claimed beneficial health effects. 
Based on this literature review, the NASEM reached the following 
conclusions about marijuana’s treatment and palliative efficacy. Cannabis 
has the following potential therapeutic effects: (1) “in adults with 
chemotherapy-induced nausea and vomiting, oral cannabinoids are 
effective antiemetics;” (2) “[i]n adults with chronic pain, patients who 
were treated with cannabis or cannabinoids are more likely to experience 
a clinically significant reduction in pain symptoms;” (3) “[i]n adults with 
multiple sclerosis (MS)-related spasticity, short-term use of oral 
cannabinoids improves patient-reported spasticity symptoms.”197 These 
studies suggest that marijuana may reduce specific symptoms currently 
treated by other medication. 
With respect to cancer risks, the NASEM reached the following 
conclusions: (1) “smoking cannabis does not increase the risk for certain 
cancers (i.e., lung, head, and neck) in adults;” (2) cannabis use may be 
“associated with one subtype of testicular cancer;” and (3) “[t]here is 
minimal evidence that parental cannabis use during pregnancy is 
associated with greater cancer risk in offspring.”198 These studies alone 
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reveal very little about potential links between marijuana use and the full 
ranges of cancer risks and nothing about the dosage-response connection 
for any specific form of cancer. 
The NASEM raised unequivocal concern about the impact of 
cannabis use on respiratory diseases (e.g. bronchitis, asthma, emphysema, 
pneumonia). With respect to respiratory diseases, there is scientific 
support for the following findings: (1) “[s]moking cannabis on a regular 
basis is associated with chronic cough and phlegm production;” (2) 
“[q]uitting cannabis smoking is likely to reduce chronic cough and phlegm 
production;” and (3) it is “unclear whether cannabis use is associated with 
COPD, asthma, or worsened lung function.”199 These studies suggest that 
marijuana may pose health risks to those suffering from mild respiratory 
diseases, such as acute bronchitis, and to those suffering from chronic 
conditions, such as emphysema and lung cancer. 
The NASEM also found scientific support for the following mental 
health risks and benefits: (1) “cannabis use is likely to increase the risk of 
developing schizophrenia and other psychoses;” (2) “in individuals with 
schizophrenia and other psychoses, a history of cannabis use may be 
linked to better performance on learning and memory tasks;” (3) “cannabis 
use does not appear to increase the likelihood of developing depression, 
anxiety, and posttraumatic stress disorder;” (4) “heavy cannabis users are 
more likely to report thoughts of suicide than nonusers;” and (5) “regular 
cannabis use is likely to increase the risk for developing social anxiety 
disorder.”200 Although clearly not definitive, the mental health research 
suggests the possibility of various psychological risks, including the risk 
of suicide, especially to users suffering from a preexisting mental health 
condition. 
Finally, despite the ambitious scope of the NASEM study, its 
principal author candidly acknowledged that any conclusions must be 
understood in the context of the current evidence void. Despite massive 
increases in use, there is very little scientifically valid evidence to support 
marijuana and almost nothing is known about the efficacy, dose, 
administration, or side effects of commercially available marijuana 
products. The current dramatic increase in legal marijuana use could 
eventually provide an increased evidence base of pot’s effects that might 
help convince the federal government to lift research obstacles.  For now, 
as principal author Dr. Donald Abrams explained, “barriers to conducting 
comprehensive research . . . mean patients and providers may lack 
treatment options and policymakers may lack a full evidence base 
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constitute[ing] a public health problem.”201 So despite the massive new 
NASEM meta-analysis, we continue to know very little about marijuana’s 
claimed health benefits and even less about potential physical and mental 
health risks. 
 b.  The World Health Organization 
In 2017, the World Health Organization (“WHO”) issued its own 
report on the potential therapeutic uses and acute and chronic effects of 
cannabis and cannabinoid use.202  With respect to the therapeutic uses of 
cannabinoids, the WHO reported that “[s]everal studies have 
demonstrated the therapeutic effects of cannabinoids for nausea and 
vomiting in the advanced stages of illnesses such as cancer and AIDS.”203 
The WHO also noted other promising therapeutic uses including 
“treatment of asthma and glaucoma, as an antidepressant, appetite 
stimulant, anticonvulsant and anti-spasmodic, [although] research in this 
area should continue.”204 This research, like the NASEM report, suggests 
that cannabis and cannabinoids may have specific health benefits for 
conditions currently treated by other medications. 
The WHO reported the following acute and chronic physiological 
and psychological effects. The developing research into acute effects 
includes evidence that: (1) “cannabis impairs cognitive development;” and 
(2) that “cannabis impairs psychomotor performance in a wide variety of 
tasks, such as motor coordination, divided attention, and operative tasks 
of many types.”205 The WHO also reported the following chronic 
physiological and psychological effects principally associated with heavy 
or long-term use: (1) “selective impairment of cognitive functioning which 
include the organization and integration of complex information involving 
various mechanisms of attention and memory processes;” (2) 
“development of a cannabis dependence syndrome characterized by a loss 
of control over cannabis;” (3) “exacerbate[ion] [of] schizophrenia in 
affected individuals;” (4) “epithelial injury of the trachea and major 
bronchi;” (5) “airway injury, lung inflammation, and impaired pulmonary 
defense against infection;” and (6) “a higher prevalence of symptoms of 
chronic bronchitis and a higher incidence of acute bronchitis.”206 This 
research echoes many of the findings of the NASEM report, but highlights 
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more specific cognitive functioning and memory concerns and addiction 
(cannabis dependency syndrome) risks. 
On the specific question of fetal health, the WHO (unlike the 
NASEM) reported that cannabis used during pregnancy is “associated 
with impairment in fetal development leading to a reduction in birth 
weight” and “may lead to postnatal risk of rare forms of cancer although 
more research is needed in this area.”207 On the issue of the inadequacy of 
the extant data and its impact on the preliminary nature of any conclusions, 
the WHO report authors agreed with the authors of the NASEM study. 
According to the WHO authors, worldwide research is insufficient and, in 
particular, “the health consequences of cannabis use in developing 
countries are largely unknown because of limited and non-systematic 
research.”208 
2.  Marijuana and the Developing Brain 
Most studies show that recreational marijuana use is more popular 
among teenagers and younger adults.209 Growing use among younger 
adults raises concerns about the potential effects of cannabis on the 
developing brain. Unfortunately, as with all other areas of nascent 
marijuana science, the neuroscience literature is inconclusive and 
contradictory. These problems are well illustrated by the few widely cited 
brain development studies. 
A 2012 study found that regular cannabis use can be “associated with 
neuropsychological decline broadly across domains of functioning,” that 
regular users “reported noticing more cognitive problems,” and that 
“impairment was concentrated among adolescent-onset cannabis users, 
with more persistent use associated with greater decline.”210 CBD has no 
recreational value. But like marijuana, new research suggests that CDB 
may have independent therapeutic potential. For example, there is recent 
“evidence that chronic pain, inflammation and insomnia are better relieved 
by cannabis high in cannabidiol (CBD).”211 However, there is also 
evidence that, without THC, CBD may not be as effective for some 
therapeutic purposes. For example, there is research suggesting that 
“[c]ancer-related nausea and poor appetite . . . are better relieved by 
cannabis high in THC, the psychotropic component of marijuana.”212 
Although the data is very limited, this suggests that the interaction between 
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CBD and THC might impact therapeutic benefits and raises questions 
about the general medical value of the myriad CBD-only products 
currently available. 
Recently, researchers began to explore the scientific therapeutic 
potential of both THC and CBD on epilepsy.213 Early studies yielded 
inconclusive results, but numerous scientists believe that epilepsy research 
merits further targeted investigation, based in part on a long history of 
anecdotal reports of reduced symptomology by epileptic cannabis users.214 
More recent research suggests that CBD may be useful for epilepsy 
treatment and that it may also have more generalized neuroprotective 
effects.215 In a clear endorsement of the quality of science in this specific 
field, in June of 2018, the FDA approved the first CBD-derived drug 
(Epidiolex) for the treatment of pediatric epilepsy.216 
CBD also showed early promise in the treatment of a range of 
neuropsychiatric disorders. In a decade-old animal study, CBD showed 
promise for the treatment of schizophrenia.217 More recently, CBD has 
been shown to have potentially beneficial effects for a “range of 
neurodegenerative conditions and psychiatric disorders.”218 These include 
the alleviation of symptoms for patients diagnosed with schizophrenia,219 
epilepsy,220 and multiple sclerosis.221 In other recent research, CBD has 
been shown to have measurable anti-anxiety, antipsychotic, antiemetic and 
anti-inflammatory properties.222 In a 2017 study, these promising 
neuroprotective effects were linked to CBD’s demonstrated antioxidant 
and anti-inflammatory activities.223 These studies suggest that CBD may 
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have a range of medical and palliative benefits creating the possibility that 
CBD might provide a non-psychoactive alternative to marijuana. 
Despite the absence of THC, CBD has already been associated with 
various health risks. Recent CBD studies report “side effects, including 
inhibition of hepatic drug metabolism, alterations of in vitro cell viability, 
decreased fertilization capacity, and decreased activities of p-glycoprotein 
[a multidrug resistant protein that serves as a cell defense to harmful 
substances] and other drug transporters.”224 This study suggests that CBD 
may pose a risk of injury to the liver, impede fertility treatment, or interfere 
with proteins that help necessary transport within the body and cell 
protection from foreign substances. 
In 2017, the WHO addressed comparative CBD and cannabis 
addiction risks.225  According to the WHO, “cannabidiol [CBD] is not [as] 
likely to be abused or create dependence as . . . other cannabinoids (such 
as Tetra Hydro Cannabinol (THC), for instance).”226 Based on this finding, 
the WHO concluded “[t]o date, there is no evidence of recreational use of 
CBD or any public health related problems associated with the use of pure 
CBD.”227 This finding may make sense, given CBD’s lack of THC, but 
because CBD remains subject to identical Schedule I restrictions – as 
“little is known about its safety and side effect profile in animals and 
humans,”228 as is known about cannabis. 
E. Physician Quasi-Acceptance 
According to a 2013 New England Journal of Medicine [NEJM] poll, 
76% of doctors favor the legalization of medicinal marijuana.229 A 2018 
Dana-Farber Cancer Institute study confirmed these findings within the 
oncological community.230 This study, which involved a random sampling 
of oncologists, noted widespread physician support and found that nearly 
50% of oncologists actually recommended marijuana to their patients.231 
However, the 2018 study also revealed that most doctors who 
recommended marijuana also expressed concern that more and better 
research is needed.232Dr. Ilana Braun, M.D., a co-author of the Dana-
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Farber study, highlighted the fact that half of the “physicians would offer 
clinical advice about a topic on which they do not feel knowledgeable[,]” 
which demonstrates “the uncomfortable spot in which oncologists find 
themselves.”233 The large number of physicians now recommending pot 
helps to prove that the law is advancing much faster than the science.234 
By 2018, medical marijuana was a legal cancer treatment in 30 states,  yet 
according to Dr. Braun, even marijuana proponents are aware that “the 
scientific evidence base supporting use of medical marijuana in oncology 
remains thin.”235 
Despite survey evidence indicating growing physician support, in 
practice, many doctors remain reluctant to prescribe or recommend 
cannabis—even in the 30 states where medical marijuana is legal.236 
Recently, Dr. Orrin Devinsky, director of New York University’s 
Comprehensive Epilepsy Center and a prominent cannabidiol researcher, 
described current practice tensions as linked to marijuana’s bizarre legal 
status: “We have the federal government and the state governments 
driving a hundred miles an hour in the opposite direction when they should 
be coming together to obtain more scientific data.”237 To the extent that 
Dr. Devinsky is accurately characterizing physician opinion, the ongoing 
Schedule I status of cannabis and CBD remains a big impediment for 
mainstream medical acceptance. 
Patients may also contribute to acceptance problems and to poor 
communication with their physicians. According to Dr. Peter Grinspoon 
of Massachusetts General Hospital: “Many patients find themselves in the 
situation of wanting to learn more about medical marijuana, but feel 
embarrassed to bring this up with their doctor. . . . Other patients are 
already using medical marijuana, but don’t know how to tell their doctors 
about this for fear of being chided or criticized.”238 To solve or alleviate 
these problems, Dr. Grinspoon offers the following suggestions: “My 
advice for doctors is that whether you are pro, neutral, or against medical 
marijuana, patients are embracing it, and although we don’t have rigorous 
studies and ‘gold standard’ proof of the benefits and risks of medical 
marijuana, we need to learn about it, be open-minded, and above all, be 
non-judgmental.”239 The advice that it is better for patients and physicians 
to speak candidly with each other is always true, although Dr. Grinsppon 
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may be correct that marijuana’s ongoing federal illegality raises specific 
concerns in the mind of both. 
IV. THE LAW OF POT 
A. Federal-State Preemption 
If we begin at the beginning, Article VI of the U.S. Constitution 
provides that “the laws of the United States . . . shall be the supreme law 
of the land; . . . any Thing in the Constitution or Laws of any state to the 
Contrary notwithstanding.”240 In the two centuries since 1819, when 
M’Culloch v. Maryland241 was decided, the Supremacy Clause has 
consistently been understood to mean that any state law found to conflict 
with a federal law governing the same activity is without effect.242 More 
recently, the Supreme Court reified the state sovereignty debate by finding 
that Supremacy Clause questions must “start with the assumption that the 
historic police powers of the States [are] not to be superseded by [any] 
Federal Act unless that [is] the clear and manifest purpose of Congress.”243 
Regardless of whether federal law or state law emerges triumphant, in all 
preemption analyses a determination of Congressional purpose must be 
the “ultimate touchstone.”244 
Congressional intent may be the “touchstone” of preemption, but 
legislative purpose is not always readily apparent. In practice, preemption 
questions typically arise under two distinct circumstances. Relatively 
simple cases arise “[w]hen Congress legalizes a private activity that has 
been banned by the states, [making] the application of the Supremacy 
Clause . . . relatively straightforward.”245 Harder cases, like the marijuana 
example, arise “[w]hen Congress bans some activity that has been 
legalized by the states, . . . [because] both the legal status and practical 
import of state law are far less obvious.”246 Preemption questions can arise 
in the full range of criminal and civil contexts where federal and state 
jurisdiction overlaps including public health and safety, civil rights 
protections, and products liability. To help accommodate these different 
problems of statutory conflicts, the Supreme Court has delineated three 
types of federal-state preemption: (1) express (2) (implied) field, and (3) 
(implied) conflict. 
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Easier cases typically involve express preemption. In these cases, a 
reviewing court must simply pinpoint the explicit congressional 
command.247 This will normally involve a specific judicial finding that 
Congress “declare[d] in express terms its intention to preclude local action 
in a given area.”248 In harder cases where there is no express congressional 
intent, field preemption can be implied. This will normally involve a 
finding that a state is “precluded from regulating conduct in a field that 
Congress has determined must be regulated by its exclusive 
governance.”249 However, field preemption requires a reviewing court to 
find a framework of federal regulation “so pervasive . . . that Congress left 
no room [in the field] for the States to supplement it”250 or a “federal 
interest . . . so dominant that the federal system will be assumed to 
preclude enforcement of state laws on the same subject.”251 Finally, and 
equally challenging, conflict preemption may only be implied when 
“compliance with both federal and state regulations is a physical 
impossibility”252 or if the challenged state law “stands as an obstacle to the 
accomplishment and execution of the full purposes and objectives of 
Congress.”253 Cases sometimes involve both implied field and implied 
conflict preemption. Under these circumstances, the Court has cautioned, 
even without evidence of a clear expression of legislative intent, 
preemption must still be “the clear and manifest [implied] purpose of 
Congress.”254 
As more states legalize medicinal and recreational pot, the potential 
preemptive effect of the CSA has been a subject of growing academic 
attention. Professor Erwin Chemerinsky has opined that “marijuana 
regulation is one of the most important federalism conflicts in a 
generation.”255 In his view, the conflict between federal criminalization 
under the CSA and state legalization “raises questions of tension and 
cooperation between state and federal governments[,] . . . forces 
policymakers and courts to address the preemptive power of federal drug 
laws. . . . [and] create debilitating instability and uncertainty on the ground 
in those states that are pioneering new approaches to marijuana control.”256 
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Other scholars disagree that marijuana’s simultaneous illegality and 
legality is destabilizing. For example, Professor Ira Robbins recently 
argued that “conflicting federal and state marijuana laws can coexist” 
because “federalism allows states ‘great latitude under their police powers 
to legislate as to the protection of the lives, limbs, health, comfort, and 
quiet of all persons.’”257 In Professor Robbins view, the theoretical tension 
has no practical import, because, in effect, “[a]ffording states broad 
authority promotes innovation and the potential for states to serve as 
smaller experimental vehicles for new ideas.”258  Tension, in Professor 
Robbin’s view, is not just unproblematic, it has social value. 
To date, many of the marijuana legalization preemption questions 
have arisen in the context of employment law and the construction of the 
Americans with Disabilities Act (“ADA”). In these cases, federal courts 
typically find implied preemption because they 
commonly hold that state marijuana laws are preempted by the CSA, 
that an employee’s use of marijuana is not protected under the ADA, 
and that an employers’ zero-tolerance (or similar) drug policy is an 
acceptable basis upon which to terminate a medical marijuana user’s 
employment, rescind a job offer, or refuse to hire a candidate.259  
To date, the Supreme Court has not addressed the preemptive effect of the 
CSA.260 If the federal decisions become more divided, this would create 
greater impetus for Supreme Court review. 
The text of the CSA, which is fundamental to any preemption 
determination, reads as follows: 
No provision of this subchapter shall be construed as indicating an 
intent on the part of the Congress to occupy the field in which that 
provision operates, including criminal penalties, to the exclusion of 
any State law on the same subject matter which would otherwise be 
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within the authority of the State, unless there is a positive conflict 
between that provision of this subchapter and that State law so that the 
two cannot consistently stand together.261 
It is important to note that this statutory language omits both: (1) an 
express Congressional command; and (2) any text supporting an argument 
that Congress expressly manifested the intent to occupy the field. In fact, 
Congress clearly expressed its intent not to occupy that field. 
This clear statutory language eliminates any plausible argument that 
the CSA creates express or implied field preemption, leaving open only 
the possibility of implied conflict preemption. At least one scholar has 
explained this congressional approach and its effect as follows: 
Arguably, . . . the preemptive effect of the CSA is not as broad as 
congressional authority could have allowed. States remain free to pass 
laws relating to marijuana, or other controlled substances, so long as 
they do not create a “positive conflict” with federal law. In interpreting 
this provision, courts have generally established that a state medical 
marijuana law is in “positive conflict” with the CSA if it is “physically 
impossible” to comply with both the state and federal law, or where 
the state law “stands as an obstacle to the accomplishment and 
execution of the full purposes and objectives of Congress.262  
Thus, the only preemption question is whether, in jurisdictions where 
marijuana is now legal, it is physically impossible to comply with both 
state and federal law. 
Using conflict preemption principles and general rules of statutory 
construction, Congress clearly intended only to “preempt any state law that 
positively conflicts with the CSA.”263 Future courts will need to decide 
whether state laws legalizing marijuana for medical and recreational use 
“create an impermissible ‘conflict’—as that term has been defined by the 
Supreme Court—with the CSA provisions prohibiting marijuana 
altogether.”264 Unsurprising, the Justices do not always agree about what 
is, and what is not, impossible. 
The specific question of implied conflict preemption in the context 
of marijuana laws has recently attracted the attention of a various legal 
authors. Professor Sam Kamin is not especially worried about preemption 
challenges to state law because in his view “federal law clearly permits 
states to draft their own marijuana regulations, even if those regulations 
 
 261. 21 U.S.C. § 903 (2012 & Supp. 2017). 
 262. TODD GARVEY, CONG. RESEARCH SERV. R42398, MEDICAL MARIJUANA: THE 
SUPREMACY CLAUSE, FEDERALISM, AND THE INTERPLAY BETWEEN STATE AND FEDERAL 
LAWS 9 (2012). 
 263. Mikos, supra note 16, at 1451. 
 264. Chemerinsky et al., supra note 84, at 102. 
 2019 HALF-BAKED: THE SCIENCE AND POLITICS OF LEGAL POT 443 
fail to mirror the federal prohibition; the CSA explicitly disclaims any 
intention to occupy the field and preempt all inconsistent state laws.”265 
According to Professor Kamin, his analysis refutes the argument that 
serious federal criminal marijuana penalties preempt lighter (or non-
existent) state law penalties for the same actions.266 In essence, Professor 
Kamin posits that a positive conflict is required (between state and federal 
law) and opines that a positive conflict does not arise when states simply 
liberalize or lift marijuana penalties, and would arise only in the 
implausible event that “the state were to require that which the federal 
government forbids that compliance with both state and federal law would 
become impossible.”267 Similarly, as Franklin Guenthner, astutely 
observed in his recent law review comment, the CSA cannot preempt 
“state laws that simply legalize the use of marijuana.”268 Legalization 
alone does not inevitably create a positive conflict because state officers 
would not be responsible for enforcing federal law.269 Under this view, to 
avoid preemption problems a state must simply avoid drafting “state laws 
that attempt to promote the sale, distribution, or consumption of 
marijuana.”270 
Unsurprisingly, state statutes legalizing marijuana do not include 
language promoting marijuana sale or use. This suggests a deliberate 
legislative effort to avoid “conflict[ing] directly with the proscriptions 
of . . . the CSA and thus becom[ing] an obstacle to its enforcement.”271 
Abjuring promotional language also precludes the possibility of creating 
additional complication in the event of a federal prosecution for aiding and 
abetting a federal crime.272 More generally, it is one thing to establish that 
marijuana use is legal in your state and quite another to make it 
recommended. 
Unresolved preemption questions are principally of interest to law 
professors. Without clear guidance from the Supreme Court, Professor 
Erwin Chemerinsky has offered a possible resolution in the form of a new 
theory of “cooperative federalism.”273 Cooperative federalism would not 
depend on finding an agreed-upon definition of a positive conflict, but 
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would instead simply allow states seeking legalization to “opt out” of CSA 
marijuana provisions, assuming the states could meet specific eligibility 
criteria established by Congress or the DOJ.274 While Professor 
Chemerinsky appears to have devised an elegant solution, it is impossible 
to accurately predict the political traction or practical feasibility of his 
approach. 
B. The Supreme Court Weighs In 
1. Approving Federal Enforcement of the CSA 
Over the past two decades, the Supreme Court has twice addressed 
the specific question of federal enforcement of the CSA. United States v. 
Oakland Cannabis Buyers’ Cooperative,275 decided in 2001, involved a 
federal enforcement action under the CSA against Jeffrey Jones and the 
nonprofit Oakland Cannabis Buyers’ Cooperative [OCBC] seeking to 
enjoin them from growing and distributing marijuana under California’s 
Proposition 215.276 When Mr. Jones and the OCBC openly violated the 
injunction, the government initiated contempt proceedings and the 
defendants argued that the distributions of marijuana were “medically 
necessary.”277 
The federal injunction had been granted by the district court; but 
when the case reached the Ninth Circuit, the court found the medical 
necessity defense legally cognizable.278 The appellate court reasoned that 
because the district court had “‘broad equitable discretion’ to fashion 
injunctive relief, that court could have, and should have, weighed the 
‘public interest’ and considered factors such as the serious harm in 
depriving patients of marijuana.”279 On remand, the district court modified 
the injunction to include a medical necessity defense.280 Ultimately, the 
Supreme Court would disagree with the Ninth Circuit on a variety of 
grounds. 
According to Justice Thomas, who wrote for the Oakland Cannabis 
Buyers’ Cooperative majority, the question of a federal court’s general 
authority to recognize a necessity defense (when such a defense is not 
specified by statute) has never been resolved.281 However, the Court did 
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not need to reach the broader jurisdictions issue to reject the specific 
medical necessity argument advanced in this case.282 Justice Thomas 
explained the Court’s reasoning as follows: 
Under any conception of legal necessity, one principle is clear: The 
defense cannot succeed when the legislature itself has made a 
“determination of values.” In the case of the Controlled Substances 
Act, the statute reflects a determination that marijuana has no medical 
benefits worthy of an exception (outside the confines of a Government-
approved research project). Whereas some other drugs can be 
dispensed and prescribed for medical use, [citation omitted] the same 
is not true for marijuana. Indeed, for purposes of the Controlled 
Substances Act, marijuana has “no currently accepted medical use” at 
all.283  
Thus, in a case that arguably should have been about the science of 
marijuana, the Court relied on a three-decade old congressional finding 
(lacking any scientific support) to defeat a medical necessity claim 
(without considering any possible supporting scientific evidence). 
In addition to illustrating the Court’s disinclination to examine the 
scientific evidence, Oakland Cannabis Buyers’ Cooperative also 
demonstrates the bizarre circular reasoning facilitated by marijuana’s 
simultaneous federal illegality and state legality. Here is the tautology: the 
“Attorney General can include a drug in schedule I only if the drug ‘has 
no currently accepted medical use in treatment in the United States,’” 
therefore the Court must find that the drug has no medical use (making 
medical necessity impossible) because the Attorney General put the drug 
into Schedule I.284 The defects in this reasoning should be obvious. First, 
science had advanced by three decades since the CSA was enacted, so any 
medical conclusions from 1970 should be reevaluated. Second, as a matter 
of logic, this is akin to arguing that insulin, if placed on Schedule I, would 
cease to regulate diabetes. The Court’s rote determination that cannabis 
has no potential medical purpose—because Congress said so three decades 
ago—is highly problematic as a matter of science, but as a matter of law 
it allowed the Court to evade the question of “medical necessity” and 
precluded the introduction of any new evidence to support the argument 
that marijuana has medical or palliative value. 
Four years later, in Gonzales v. Raich,285 the Supreme Court upheld 
enforcement of the CSA against California medical marijuana producers 
on different grounds—as a proper exercise of Congressional Commerce 
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Clause power.286 Like Oakland Cannabis Buyers’ Cooperative, Raich 
arose after state and federal law enforcement officers had raided plaintiffs’ 
home and DEA agents had seized and destroyed plaintiffs’ marijuana 
plants because they were grown in violation of the CSA.287 The Raich 
Court specifically rejected the plaintiffs’ argument that the seized 
marijuana was being used solely “for personal medical purposes on the 
advice of a physician;” ruling instead that Congress has the authority to 
designate marijuana “as contraband for any purpose.”288 
On the question of medicinal use, the Court again avoided the 
scientific merits and simply echoed the circular reasoning of Oakland 
Cannabis Buyers’ Cooperative, holding that such use was impossible 
because “Congress expressly found that the drug has no acceptable 
medical uses.”289 As with the earlier case, the judicial determination that 
cannabis has no possible medical use because Congress said so almost four 
decades earlier, made any plaintiffs’ evidence of marijuana’s therapeutic 
value irrelevant to the determination. 
The Raich Court’s Commerce Clause analysis was as problematic as 
its evaluation of the evidence. The seized marijuana had been grown, sold, 
and used solely in California.290 All of the materials necessary for its 
cultivation had also been carefully purchased within the state. Based on 
these facts, the plaintiffs argued that the CSA’s “categorical prohibition,” 
as applied here to the wholly “intrastate manufacture and possession of 
marijuana for medical purposes,” exceeded Congress’s authority to 
regulate interstate commerce.291 
The Raich Court began its analysis by reviewing the three modern 
forms of Commerce Clause authority: 
First, Congress can regulate the channels of interstate commerce. 
Second, Congress has authority to regulate and protect the 
instrumentalities of interstate commerce, and persons or things in 
interstate commerce. Third, Congress has the power to regulate 
activities that substantially affect interstate commerce [citations 
omitted].292 
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The Court quickly concluded that only the third “substantial effect” 
category could be implicated by plaintiffs’ actions.293 Thus, the question 
for the Court was whether Congress has the “power to regulate purely local 
activities that are part of an economic class of activities that have a 
substantial effect on interstate commerce.”294 
Quoting Wickard v. Filburn,295 the Raich Court observed that “even 
if appellee’s activity be local and though it may not be regarded as 
commerce, it may still, whatever its nature, be reached by Congress if it 
exerts a substantial economic effect on interstate commerce.”296 Ignoring 
both the real-world and analytic distinctions between the congressional 
regulation of national wheat prices, at issue in Wickard, and the intrastate 
cultivation and home use of small amounts of marijuana for personal 
medicinal purposes, the Court found that the inevitable diversion of 
marijuana into the national market would affect interstate commerce.297 
The Raich decision seemed to ignore the basic facts and to rest, at least 
partly, on the Court’s use of a four-decade-old Webster’s dictionary 
definition of “economic” that included the “production of goods.”298 More 
notably, the Court simply ignored the critical requirement of proof of a 
“substantial” economic impact.299 Justice Scalia, who wrote for the 
majority, made no effort to quantify the economic impact of the activities 
at issue simply said “[w]e have never required Congress to legislate with 
scientific exactitude.”300 Raich suggests that the Court will effectively 
presume, despite all apparent evidence to the contrary, that certain 
activities will have some effect on interstate commerce. 
2. Critique of the Modern Approach to Commerce Clause 
Authority 
The Raich decision has been soundly criticized as an unconstitutional 
expansion of Commerce Clause authority. It has also been specifically 
cited as evidence of the Rehnquist Court’s federalism inconsistency and  
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of the Court’s growing politicization. 
Despite its billing as the protector of states’ rights, the [Raich] Court 
gave almost as expansive an account of federal power under the 
Commerce Clause as could be imagined. In order to sustain the 
claimed federal interest, the Court had to find that, as applied, the CSA 
was a valid exercise of the federal legislative power, notwithstanding 
the lack of engagement of the home-grown marijuana with any 
economic markets, intrastate or interstate.301 
Writing in dissent in Raich, Justice O’Connor, argued that the decision had 
improperly expanded federal powers to intrude into intrastate concerns 
and to the detriment of other governmental interests. In her opinion, one 
of federalism’s “chief virtues” is the promotion of innovation.302 
Innovation occurs because “a single courageous State may, if its citizens 
choose, serve as a laboratory; and try novel social and economic 
experiments without risk to the rest of the country.”303 According to Justice 
O’Connor, Raich exemplified the virtue of state innovation, but the Court 
had applied the CSA to “extinguish[] that experiment, without any proof 
that the personal cultivation, possession, and use of marijuana for 
medicinal purposes, if economic activity in the first place, has a substantial 
effect on interstate commerce and is therefore an appropriate subject of 
federal regulation.304 Raich was also a complete departure from the 
fundamental federalism principles articulated in just ten years earlier in 
United States v. Lopez.305 
A similar critique has been advanced by various legal scholars. 
Shortly after Raich was decided, Professor Thomas Merrill opined that the 
decision signaled the Court’s “ill-advised” federalism shift away from 
clear rules and towards prohibitory limitations.306 In 1955, in United States 
v. Lopez,307 the Court had upheld a federal “Gun-Free School Zones Act,” 
based on a finding that the possession of a gun in school has no impact on 
interstate commerce.308 According to Professor Merrill, Justice 
O’Connor’s discussion of Lopez was intended to serve as a reminder that 
Congressional ability to regulate intrastate commerce is strictly limited to 
those activities that have a “substantial effect on interstate commerce [and] 
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only if that activity is ‘economic’ in nature.”309 In Professor Merrill’s 
opinion, in Raich makes it “difficult to see how growing and consuming 
marijuana at home for medicinal purposes is ‘economic’ activity,” which 
should have placed it “beyond the power of Congress to regulate under 
Lopez.”310 But in his view, after Raich, “Lopez’s prohibitory rule was 
watered down to the point where it may have little continuing 
significance.”311 Both Justice O’Connor and Professor Merrill would 
apparently agree that the same Commerce Clause powers the Court strictly 
when a state sought to ban gun possession in school was inexplicably 
expanded when an individual sought, in accordance with state law, to grow 
and use medical marijuana in his home. 
Since Raich, the Supreme Court has avoided the marijuana debate. 
Most notably, in 2016, the Court declined by a vote of 6-2 (with Justices 
Thomas and Alito dissenting), a challenge by Nebraska and Oklahoma to 
Colorado’s recreational use law.312 Nebraska and Oklahoma had alleged 
that the new Colorado law violated federal drug laws and “increased 
trafficking and transportation of Colorado-sourced marijuana into their 
territories, requiring them to expend significant law enforcement, judicial 
system, and penal system resource to combat the increased trafficking and 
transportation of marijuana.”313 
The Court’s 2016 decision declining to hear Nebraska v. Colorado314 
was viewed as a victory by marijuana legalization proponents. According 
to Tom Angell, chairman of Marijuana Majority, “[t]here’s no question 
about it: This is good news for legalization supporters. This case, if it went 
forward and the Court ruled the wrong way, had the potential to roll back 
many of the gains our movement has achieved to date.”315 
C. The Tenth Amendment 
1. The Anti-Commandeering Doctrine 
The Tenth Amendment provides that the “powers not delegated to the 
United States by the Constitution, nor prohibited by it to the States, are 
reserved to the States respectively, or to the people.”316 In Raich, the Court 
clarified that the Commerce Clause provides Congress with the authority 
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to regulate marijuana. Although the Raich Court’s Commerce Claus 
decision was clear with respect to the Congressional authority question, 
any effort at federal enforcement of the CSA raises independent and 
complicated Tenth Amendment concerns. 
Federal enforcement of the CSA against the states would implicate 
the Tenth Amendment’s “anti-commandeering doctrine.” The anti-
commandeering doctrine bars the federal government from forcing states 
to enact laws or forcing states to assist the federal government in enforcing 
federal law within a state.317 The “anti-commandeering” doctrine, as 
described by the Court in 1997 in Printz v. United States,318 bars Congress 
from imposing duties on state or local government officials including law 
enforcement. In Printz, another case involving gun control legislation, the 
Court refused to require state and local officials to comply with federal 
legislation requiring background checks on prospective handgun 
buyers.319 With Printz a notable exception, the anti-commandeering 
doctrine has traditionally been of little practical import. Congress has 
rarely attempted to commandeer state officials, and the Court has rarely 
relied on this doctrine to strike down a federal statute.320 
The anti-commandeering doctrine could play a greater future role in 
cases where state and federal marijuana laws conflict. This doctrine, which 
supports a strict divide between federal and state control, could help 
impede any future CSA enforcement efforts “because it essentially tells 
the federal government that it is on its own when it comes to enforcing its 
own drug laws.” 321 While the federal government might continue to 
successfully argue that marijuana is illegal under the CSA, its illegal status 
may be of little practical import, because “state and local officials cannot 
be forced to arrest or charge anyone with a violation of the CSA.”322 In 
effect, the anti-commandeering doctrine makes it very unlikely that, in 
states where marijuana is now legal, state law enforcement would ever 
play a role in enforcing federal law. 
In a very interesting new article, Professor Sam Kamim speculated 
that the Court’s May 2018 anti-commandeering decision in Murphy v. 
NCAA,323 striking down a federal law that had prohibited states from 
legalizing sports gambling, has significant implications for the future of 
marijuana legalization.324 According to Professor Kamin, the Murphy 
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decision portends that “the federal government cannot prohibit states from 
implementing marijuana law reform. Just as it cannot force the states to 
enforce the federal marijuana prohibition, it cannot require them to keep 
their own prohibitions in place, or force states that have regulated and 
taxed marijuana to undo such laws.”325 If Professor Kamin is correct that 
Murphy has paved the way for states to make individualized marijuana 
decisions, this would be welcome news for legalization proponents. 
Of course, the anti-commandeering doctrine does not prevent the 
federal government from using federal law enforcement officers to enforce 
the CSA. Although the Constitution cannot prevent federal law 
enforcement, robust enforcement is highly unlikely because it would be 
impracticable. As more states “implement laissez-faire statutes toward 
marijuana consumption and distribution, the Justice Department will have 
to allocate more of its own resources toward the investigation, prosecution, 
and imprisonment of the hundreds of thousands of marijuana offenders 
arrested and charged each year.”326 This scenario is improbable because 
the “federal government lacks the resources needed to enforce its own ban 
vigorously: although it commands a $2 trillion dollar (plus) budget.”327 In 
practice, “the federal government is only a two-bit player when it comes 
to marijuana enforcement. . . . [with] [o]nly 1 percent of the roughly 
800,000 marijuana cases generated every year . . . handled by federal 
authorities.”328 Given the economic realities, the largest impediment to 
federal enforcement of the CSA is not deference to the states or a change 
of heart about criminality, but federal inability to manage massive 
additional policing costs. 
2. Congressional Spending Power 
Congress also has spending power (i.e., the power of the purse), 
which it can use to steer the enforcement of federal law by state law 
enforcement. In effect, Congress has the inherent power to shape state 
public policy “by enacting spending legislation aimed at inducing states to 
adopt certain approaches to public health problems.”329 However, 
congressional spending power has well-established limits. 
National Federation of Independent Business v. Sebelius,330 the 2012 
landmark case upholding the constitutionality of the Patient Protection and 
 
 325. Sam Kamin, Murphy v. NCAA: It’s About Much More Than Gambling on Sports, 
THE HILL (May 15, 2018, 8:00 AM), http://bit.ly/2SLdZth. 
 326. Guenthner, supra note 268. 
 327. Mikos, supra note 16, at 1424 (2009). 
 328. Id. 
 329. Sara Rosenbaum, Gonzales v. Raich: Implications for Public Health Policy, 120 
PUB. HEALTH REPS. 680, 682 (2005).  
 330. Nat’l Fed’n of Indep. Bus. v. Sebelius, 567 U.S. 519 (2012). 
 452 PENN STATE LAW REVIEW Vol. 123:2 
Affordable Care Act (ACA or “Obamacare”), would likely govern any 
future congressional spending power inquiry. In relevant part, the 
Supreme Court held that the Congress could not compel states to expand 
Medicaid by threatening to withhold funding for existing state Medicaid 
programs.331 The Court reasoned that this exercise of federal spending 
power would violate constitutional separation of powers.332 According to 
the Court, Spending Clause legislation cannot be used to undermine the 
sovereign power of the individual states.333 Although Sebelius provides a 
recent unequivocal delineation of spending power limits, the case rests on 
earlier spending power cases, in which the Court held that the separation 
of powers previous decisions holding that Congress cannot use its 
spending power authority to demand that states “govern according to 
Congress’ instructions.”334 
In sum, although Congress could try to use its spending authority to 
restrict funds to state that fail to recriminalize marijuana, this strategy 
might be unconstitutional. The Sebelius Court recently held that 
Congress’s coercive use of its conditional spending power raises 
constitutional concerns similar to those implicated under the Tenth 
Amendment anti-commandeering doctrine.335 As Professor Mikos 
predicted, conditional federal spending would likely be viewed as a 
congressional effort to “sidestep jurisprudential limits on its authority and 
accomplish otherwise impermissible objectives.”336 Conditional spending 
power is viewed with skepticism as one of “federalism’s Trojan 
Horses.”337 The risk, in the marijuana context, is that any Congressional 
effort to incentivize the recriminalization of marijuana would be an effort 
to supplant the legislative authority and judgment of duly elected state 
officials and voters. 
V. CONCLUSION: POT’S UNCERTAIN POLITICAL FUTURE 
A. Recent Executive Branch Shifts 
Although the status of marijuana as a Schedule I drug has been 
constant for the past half-century, the modern history of federal  
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enforcement policy has been wildly inconsistent. 
The United States Justice Department under the Clinton 
Administration took the position that the CSA did not apply to 
Schedule I drugs such as marijuana in states with medical use laws. 
However, the Bush Administration adopted a contrary position that, 
state law notwithstanding, any personal possession of marijuana, even 
for medical reasons and without any evidence of sale or commercial 
purposes, amounted to a criminal violation of the CSA. In effect, the 
Bush Administration eliminated its predecessor’s medical use 
exception.338 
In 2009, in response to growing tension between state decriminalization 
efforts and marijuana’s Schedule I status, the Deputy Attorney General 
David Ogden issued a policy memorandum, which attempted to resolve 
this conflict (the “Ogden Memo”).339 
The Ogden Memo reiterated that “the Department of Justice is 
committed to the enforcement of the Controlled Substances Act in all 
States[,] [that] Congress has determined that marijuana is a dangerous 
drug, and [that] the illegal distribution and sale of marijuana is a serious 
crime and provides a significant source of revenue to large-scale criminal 
enterprises, gangs, and cartels.”340 However, in an effort to “mak[e] 
efficient and rational use of its limited investigative and prosecutorial 
resources,” the federal prosecution of “significant traffickers of illegal 
drugs, including marijuana, and the disruption of illegal drug 
manufacturing and trafficking networks [would] continue to be a core 
priority.”341 But federal resources would no longer be directed to the 
investigation and prosecution of any “individuals whose actions are in 
clear and unambiguous compliance with existing state laws providing for 
the medical use of marijuana.”342 The Odgen Memo drew a firm 
distinction between drug trafficking and distribution and person medical 
use as permitted by state law. 
The following policy statement from then Attorney General Eric 
Holder accompanied the release of the Ogden Memo: 
It will not be a priority to use federal resources to prosecute patients 
with serious illnesses or their caregivers who are complying with state 
laws on medical marijuana, but we will not tolerate drug traffickers 
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who hide behind claims of compliance with state law to mask activities 
that are clearly illegal.343 
At the time of the Ogden Memo, the DEA website included the 
following warning: “Smoked marijuana has not withstood the rigors of 
science — it is not medicine and it is not safe. [But the DEA] targets 
criminals engaged in cultivation and trafficking, not the sick and dying.”344 
Years earlier, on August 29, 2013, then U.S. Deputy Attorney General 
James M. Cole had released a memo announcing that the Department of 
Justice would not allocate any resources to efforts to overturn marijuana 
legalization under state law.345 
The transition from the Obama administration to the Trump 
administration has been accompanied by many policy changes. On 
January 4, 2018, then Attorney General Jeff Sessions rescinded the Ogden 
Memo and reversed the five-year-old Obama policy346 of non-interference 
with states that have decriminalized or legalized marijuana use.347 By 
2018, more than half of the states had decriminalized medical marijuana, 
and at that time eight states also allowed the possession of small amounts 
of marijuana for recreational use.348 The Trump administration’s 
announcement came just three days after the legalization of recreational 
marijuana in California following a decade of widely available medical 
marijuana throughout the state.349 
The Trump administration announcement was a reversal, not just of 
Obama’s policy, but also of candidate Trump’s specific campaign pledge 
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to leave marijuana-related decisions to the states.350 It is also worth noting 
that one month later, Sessions released a memo on private prisons 
reversing the Obama Administration’s plan to phase out private prisons.351 
To the extent that the Obama-era marijuana policy was intended to help 
reduce incarcerations for minor marijuana possession offenses, the Trump 
administration’s rescission of this policy would have the opposite effect 
creating a crop of new inmates and more profits for private prisons and 
their owners.352 
Recent Trump administration decisions are not only inconsistent with 
campaign promises, but they do not reflect public opinion as shown by 
recent political polling data. Currently, 71% of U.S. voters do not approve 
of federal government intervention into state decisions decriminalizing 
marijuana.353 Current DOJ policy is consistent with Session’s 
longstanding personal antipathy towards pot. Before serving as Attorney 
General, Sessions was widely-quoted as saying that “good people don’t 
smoke marijuana.”354 While serving as Attorney General, Sessions had 
sent a letter to Congress warning that state marijuana legalization spawns 
the growth of black markets and increases interstate marijuana 
commerce.355 Finally, in what sounds too much like Breaking Bad-induced 
confusion, Sessions also blamed marijuana legalization for causing 
numerous deadly lab explosions.356 Although it is impossible to accurately 
predict whether the new Trump policies will result in more prosecutions 
and incarcerations, by disrupting the Obama era détente they will 
exacerbate tensions between federal and state law and enforcement 
objectives. 
B. Recent Federal Legislative Initiatives 
1. The Marijuana Justice Act (2017) 
A few months before Sessions rescinded the Ogden Memo, Senator 
Cory Booker waded into the public debate by introducing the Marijuana 
Justice Act of 2017.357 This multi-purpose law offers a radically different 
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approach to the same federal vs. state conflict, because Senator Booker’s 
proposal would fully legalize marijuana at the federal level.358 
In addition to eliminating legal and enforcement inconsistencies, 
Senator Booker is specifically focused on broader social justice objectives. 
The Marijuana Justice Act seeks to reduce or eliminate the disparate socio-
economic, racial, and ethnic impact of marijuana arrests and prosecutions. 
The Act, would “incentivize states through federal funds to change their 
marijuana laws if those laws were shown to have a disproportionate effect 
on low-income individuals and/or people of color.”359 The Marijuana 
Justice Act would involve conditional federal spending and its future 
remains uncertain, but its explicit social justice goals would likely received 
some congressional support. 
2.  The VA Medicinal Cannabis Research Act (2018) 
On May 8, 2018, a House committee approved cannabis legislation 
that would encourage the U.S. Department of Veterans Affairs (the 
“V.A.”) to conduct research on marijuana’s medical benefits.360 
Specifically, the VA Medicinal Cannabis Research Act of 2018 would 
allow and support research relating to the safety and efficacy of marijuana 
to treat veterans diagnosed with chronic pain, post-traumatic stress 
disorder, and other conditions.361 According to the American Legion, 
which is a congressionally chartered Veteran Service Organization, as of 
October 2017, over 90% of all veterans surveyed support medical cannabis 
research and over 80% of veterans also support legalizing medical 
marijuana.362 The American Legion also reported that over 22% of 
veterans already use cannabis to treat some type of medical condition.363 
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However, the legislative fate of the VA Medicinal Cannabis Research 
Act of 2018 may be irrelevant. In a surprising decision, on July 25, 2018, 
the V.A. announced that it would not recommend or even study the use of 
medical marijuana to treat veterans.364 The public response was 
immediate. The New York Times responded in an op-ed by citing “a 
disconnect in care”365 by the Veteran’s Administration. According to the 
Times’ editors, the V.A. “has funded lots of marijuana studies, but not of 
therapeutic potential. All the work has been related to problems of use.”366 
A V.A. spokesman, who failed to address the substantive concern that 
abuse merited attention but medical potential did not, simply stated that 
the bill did not change marijuana’s current Schedule I status.367 
Current VA policy is an abrupt shift away from the position espoused 
by Dr. David J. Shulkin, the Trump Administration’s first Secretary of 
Veterans Affairs. Dr. Shulkin had specifically recommended that “the 
tangle of red tape surrounding Schedule 1 drug studies” be reduced to 
facilitate cannabis research.368 According to Dr. Shulkin, medical 
marijuana could be especially important to veterans: “We have an opioid 
crisis, a mental health crisis, and we have limited options with how to 
address them, so we should be looking at everything possible.”369 To date, 
the V.A. has not publicly explained the reason for this abrupt shift in policy 
or its complete disinterest in exploring marijuana’s potential therapeutic 
benefits for the community it serves. 
C. Confounding Political Factors 
1. The Opioid Crisis 
The opioid addition crisis further complicates marijuana policy. The 
recent increases in both medicinal and recreational cannabis use had been 
attributed (at least in part) to growing awareness of the significant health 
risks of opioid abuse and addiction.370 
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The extant data on any possible link between marijuana and opioid 
use is inconclusive. The evidence may eventually establish a worrisome 
association between marijuana use and opioid use or it may prove that 
marijuana is a helpful and effective substitute for opioids for some 
palliative purposes and/or that marijuana can be used to limit opioid 
reliance. 
Recent research suggests that marijuana may form one part of an 
opioid crisis solution. In a study presented at the May 2018 meeting of the 
American Geriatrics Society, medical marijuana was linked to effective 
efforts to curb the opioid overuse—especially for older patients living with 
chronic pain from osteoarthritis, spinal stenosis, or pain from hip and knee 
joints that could not be replaced.371 Dr. Diana Martins-Welch, a co-author 
of the study, stated: “What I’m seeing in my practice, and what I’m hearing 
from other providers who are participating in medical marijuana programs, 
is that their patients are using less opioids.”372 If others can replicate these 
findings, it would incentivize future research into marijuana substitution 
for opioid users. 
But policymakers, voters, and consumers should not misconstrue a 
public push to replace opioids with cannabis as evidence that cannabis is 
benign or has no addiction risks. Currently, “public perception 
surrounding the use of medicinal cannabis suggests that this plant-based 
therapy is viewed as not much different than a botanical drug product or 
supplement used for health or relief of symptoms if disease persists.”373 
Marijuana is demonstrably safer than opioids; there has never been a 
reported death from a marijuana overdose.374 However, as shown above, 
the data on marijuana and addiction is incomplete and inconclusive, and 
its long- and short-term physiological and psychological effects are 
virtually unknown. Given the paucity of the scientific evidence, any 
assumption that cannabis must be healthy because it is a botanical, is 
ridiculously naive. 
2. Scientific Illiteracy, “Truthiness,” and Empirical 
Relativism 
Good marijuana law must be based on good marijuana science. But 
our 50 years commitment to maintaining marijuana as a Schedule I 
substance has guaranteed that the stagnant science cannot keep pace with 
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the changing law. But, as with all other twenty-first century science and 
law problems, the lack of evidence is not the only impediment to clear 
thinking and sound public policy. 
Pro-legalization state legislators seeking new revenue streams have 
little interest in demanding more scientific data that could reveal the risks 
of marijuana. Their constituents are similarly disinclined to advocate for 
more research. When voters support or oppose legalization, they are 
unlikely advocates for better research because we are an increasingly 
scientifically illiterate population that simply fails to recognize the 
unknown information we actually need. Americans have a shocking and 
increasing unfamiliarity with fundamental scientific facts and methods 
including the relationship between the earth and sun, and cannot answer 
basic questions about earth’s history including when humans ever rode 
dinosaurs.375 Our scientific ignorance becomes more problematic when 
combined with a growing disinclination to question our own beliefs and 
instant Internet access to unreliable confirmatory information. As these 
sociological factors work together, they are “dramatically reshaping our 
relationship to the world of knowledge”376 by “unmoor[ing] information 
from the context required to understand it.”377 Once considered inarguable 
fact, scientific information is increasingly dismissed as mere opinion. 
This relativistic approach to science-based questions raises important 
concerns. The philosopher Susan Haack has predicted: 
As science progresses, it tends to get more expensive; in part because 
many, if not most, of the easily- and cheaply-obtainable results have 
been obtained already, and in part, because, as the work becomes more 
complex, it also becomes more costly . . . . As scientific work becomes 
more expensive, it must rely more and more on governments and large 
industrial concerns for support; and these, obviously, are apt to give 
priority to quite other values than the epistemological norms at the 
heart of the scientific enterprise.378 
In the similarly prescient words of Stephen Colbert: 
Truthiness is tearing apart our country, and I don’t mean the argument 
over who came up with the word. I don’t know whether it’s a new 
thing, but it’s certainly a current thing, in that it doesn’t seem to matter 
what facts are. It used to be, everyone was entitled to their own 
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opinion, but not their own facts. But that’s not the case anymore. Facts 
matter not at all. Perception is everything.379 
A value-laden or “truthiness” approach to scientific inquiry cannot 
produce valid evidence, except by chance. 
In the marijuana context, legalization proponents may appeal to a 
scientifically ignorant voting public, by touting marijuana as a medical 
cure-all or a safe alternative to opioids or alcohol. Voters unsophisticated 
about the rigor of scientific research and testing will simply assume they 
have adequate information.  Under these circumstances, the impetus for 
better scientific information can only come from the scientific community. 
American scientists hamstrung by marijuana’s Schedule I status and 
unable to compete with foreign counterparts have made no headway on 
this problem for the past fifty years.  It is possible, but far from certain, 
that the current massive shift to greater marijuana use will provide 
increased evidence of its effects and provoking the federal government to 
remove current research obstacles. 
I have written elsewhere about the harm that courts cause policy 
makers and the public when they engage in extralegal judicial decision-
making without predicate empirical evidence.380 In the marijuana context, 
future decision maker (judges, lawmakers, voters, and consumers) who 
seek accurate information about marijuana’s benefits and risks online or 
from unreliable media sources will almost invariably be misinformed. In 
the context of mainstream “respectable” media, there is a ubiquitous 
tendency to present a “balanced” view on virtually every question of 
natural or social science.381 In many contexts, this balance falsely suggests 
an empirical equivalence–even when the evidence for one side is 
overwhelming (e.g., natural selection, global warming, childhood vaccine 
safety). For example, the physiological and psychological risks of 
marijuana use, especially regular use by adolescents may be significant 
and its benefits uncertain. These concerns are not in equipoise. As decision 
makers consider marijuana, the mainstream media is not the only problem. 
Although we typically turn to medical and scientific published for valid 
evidence, a shocking number of medical and scientific articles are 
published without critical information, including authors’ conflicts of 
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interests.382 Thus, sources of information can educate or contribute to 
confusion and bad decisions. 
Finally, the future of evidence-based marijuana decision making is 
threatened by the problems that arise based on incomplete information. All 
science-based law and policy questions require that decision makers 
accept or reject arguments about causation. Dr. Frank C. Keil, Director of 
the Yale Cognition and Development Lab, has found that decisions about 
causation based on incomplete information can be especially problematic 
because “[p]eople of all ages tend to be miscalibrated with respect to their 
explanatory understandings; that is, they think they understand in far more 
detail than they really do how some aspect of the world works or why some 
pattern in the world exists.”383 In order “[t]o assess how well people deal 
with causal complexity . . . one must first know when one is in over one’s 
head.”384 Marijuana decision makers operating without an extant base of 
valid scientific evidence will need better methods “of sensing when there 
are gaps in one’s knowledge that make one’s understanding so flawed that 
it is inadequate for use in a task.”385 Like the problems that arise when 
decisions about science are made by the scientifically ignorant, this 
involves the near-impossible tasks of recognizing deficits in information 
and understanding. 
Although not a panacea, decision-making research from behavioral 
economics could prove helpful. Professor Brendan Nyhan of Dartmouth 
College has examined the impact of providing accurate scientific 
information to parents deciding whether to vaccinate their children.386 
Professor Nyhan’s research showed that parents with mixed or negative 
feelings toward vaccines who were provided with accurate information 
about medical benefits and risks paradoxically “became less likely to say 
they would vaccinate a future child after receiving information debunking 
the myth that vaccines cause autism.”387 Given the obstacles to developing 
a more accurate and comprehensive scientific data on marijuana’s 
physiological and psychological effects, Professor Nyhan’s research 
suggests that the evidence is not enough.  To facilitate the development 
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science-based public policy, presentation of future data (or data from 
overseas) must be accompanied by information designed to accommodate 
conscious and unconscious emotional reactions to marijuana use as a 
medicine or palliative, or for recreation. If marijuana is not removed from 
Schedule I, marijuana research will likely only proceed in narrow areas of 
research reflecting public health priorities. The best example is the June 
2018 FDA approval of the CBD-derived drug (Epidiolex) to treat pediatric 
epilepsy.388 
The current rush towards state marijuana legalization raises 
interesting and vital new science-based legal questions and resulting 
policy decisions will redound beyond the pot-smoking/vaping/eating 
electorate. As with every science-based social question, our “democratic 
society depends on the ability of its members to make rational choices . . . 
. [and] [i]f we can’t tell the difference between reasonable and 
unreasonable claims, we become susceptible to the claims of charlatans, 
scoundrels, and mountebanks.”389 As a 2017 Harvard/National Science 
Foundation study recently warned, if Americans continue to approach new 
empirical questions with “[m]isperceptions about the scientific and 
political world,” as a 2017 Harvard/National Science Foundation study 
recently warned, these questions will aggregate and “pose a fundamental 
threat to democracy, undermining citizens’ ability to make decisions that 
effectively promote both individual self-interest and the social good.”390 
The rapid legalization of medical and recreational marijuana does not end 
the science-law debate. Instead it is the first step in a decision chain 
implicating the reach of national drug policy, the depth of state 
sovereignty, and how we will fulfill our shared obligation to ensure the 
health and safety of our citizenry. 
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